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1. Zusammenfassung 
Alveolarmakrophagen (AM) besiedeln die Oberfläche des Alveolarepithels und 
übernehmen so die Abwehrfunktion der unteren Atemwege. Zudem spielen AM eine 
wichtige Rolle bei der Pathogenese vieler entzündlichen Lungenerkrankungen wie z.B. 
Asthma und COPD. Eine notwendige Voraussetzung für diese besonders spezialisierten 
geweberesidenten Makrophagen ist ihre Plastizität, die es ihnen erlaubt sich 
entsprechend der jeweiligen Umweltgegebenheiten anzupassen und ihre 
Aktivierungsform (auch Polarisierung genannt) zu verändern. So können auch AM wie 
für andere Makrophagen bekannt, klassisch aktiviert werden (M1 Form) und einen pro-
inflammatorischen Status einnehmen, oder alternativ (M2 Form) in einen anti-
inflammatorischen Phänotyp polarisiert werden.  
Das Immunoproteasom (IP) ist eine besondere Form des Proteasom. Es besitzt drei 
Interferon gamma (IFNγ) induzierbare katalytisch aktive Untereinheiten, nämlich die Low 
Molecular Mass Protein 2 (LMP2) und 7 (LMP7), sowie die Multicatalytic Endopeptidase 
Complex-Like 1 (MECL-1) Untereinheit, welche die katalytischen Untereinheiten 1, 2, 
und 5 des konstitutiven Proteasomes entsprechend ersetzen können. Abgesehen von 
seiner wichtigen Rolle bei der Antigenpräsentation, werden neuerdings für das IP neben 
Funktionen in der erworbenen Immunität auch Wirkungswege in der angeborenen 
Immunität beschrieben.  Am besten untersucht wurde unlängst jedoch seine Funktion in 
der T-Zell Biologie, insbesondere bei T-Zell Survival und Expansion sowie bei der 
Differenzierung  von Th17  Zellen. 
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In Anbetracht der erwähnten zentralen Bedeutung der Zellplastizität von 
Alveolarmakrophagen für die Abwehrfunktion und Homöostase der Lunge, und in 
Verbindung mit der Rolle des Immunoproteasom für zellbiologische und immunologische 
Pathways, wird im Kapitel 1 (Capter 1) die Untersuchung der Funktion des IP bei der AM 
Polarisation beschrieben.  Wir zeigen hier, dass primäre aus der Mauslunge isolierte 
-4 in M2-
Phänotypen polarisiert werden können. Beide AM Aktivierungsformen weisen dabei eine 
verstärkte Expression und Aktivität der IP Untereinheiten LMP2 und LMP7 auf. Die 
Verwendung von aus Knockout-Mäusen isolierten AMs zeigte weiter, dass die Induktion 
der M1-Marker in LMP2 und -7 defizienten (LMP2-/-; LMP7-/-) nicht verändert wurde. 
Die M2-Marker dagegen waren in LMP2-/- und LMP7-/- AM eindeutig erhöht. Demen 
sprechend konnten wir weiter darstellen, dass unter M2-Bedingungen, die für den IL-4 
signalweg bekannte Phosphorylierung der Mediatoren AKT und STAT6 verstärkt auftrat. 
Darüber hinaus zeigte sich auch der für die M2-Polarisierung wichtige 
Transkriptionsfaktor IRF-4 sowohl nach IL-4 als auch IL-13 Stimulation in seiner 
Expression in LMP7-/- Zellen stark erhöht. Schließlich konnten wir zeigen, dass die 
Protein aber nicht die mRNA Expression des für die IL-4 und -13 Signaltransduktion 
gemeinsamen Rezeptors IL-4R -/- und -7-/- Zellen verstärkt war. Die daraus 
abgeleitete Hypothese, dass ein Mangel an IP Aktivität in LMP2-/- und -7-/- AM zu einer 
verstärktem IL-4R Expression führt und damit zu einer gesteigerten Sensibilität für die 
IL-4/13 Stimulation, welche wiederum eine erhöhte M2-Marker Expression bewirkt, 
konnte durch die Verwendung des neuen LMP7-spezifischen Inhibitors ONX0914 
bestätigt werden. 
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Zusammenfassend zeigen unsere in Kapitel 1 dargelegten Untersuchungen, dass eine 
LMP2 oder -7 Hemmung die M2-Polarisierung von Alveolarmakrophagen durch 
Modulation der IL-4 Rezeptor Expression verstärkt. Da diese Wirkung für die LPS/IFN
Stimulation bedeutungslos ist wird die M1-Polarisierung durch die LMP-Aktivität nicht 
beeinflusst. Die gezielte pharmakologische Hemmung von Immunoproteasom-
Untereinheiten stellt somit eine neue therapeutische Möglichkeit dar die Immunität der 
Lunge gezielt zu beeinflussen. 
Das 2. Kapitel (Chapter 2) befasst sich mit Zell-Zell Kommunikation von Alveolarzellen, 
nämlich der Alveolarmakrophagen mit den Typ 2 Pneumozyten (Typ 2 
Alveolarepithelzellen; AEC-II). Ziel dieses Projektes war es zelluläre Faktoren zu 
identifizieren die von AMs in Abhängigkeit ihrer Aktivierung (Polarisation) freigesetzt 
werden und damit die AEC-II Funktion beeinflussen. Es wurden zu diesem Zweck 
Kontakt Co-Kulturen (Transwell Co-Kultur) der SV40 immortalisierten, murinen AM-
Zelllinie MH-S mit der aus Maus Lungenadenom abgeleiteten AEC-II Zelllinie LA-4 
durchgeführt. Zudem wurden AEC-II Kulturbedingungen mit AM-konditioniertem Medium 
benutzt um explizit die durch lösliche Faktoren meditierte Interaktion zu betrachten. Es 
zeigte sich, dass in Kontakt Co-Kulturen die M1 polarisierten MH-S Zellen die 
Expression von einigen immunrelevanten AEC-II Genen, insbesondere Il6, Tgfb1, Lcn2, 
Csf2, Ccl2 und Cx3cl1 in den LA-4 Zellen stark induzieren. Die Kultivierung von LA4 
Zellen in von M1 polarisierten MH-S Zellen konditioniertem Medium, beeinflusste 
dagegen nur die Expression von Il6, Lcn2, Ccl2 und Cx3cl1 jedoch nicht die von Tgfb1 
und Csf2. Die Verwendung von mit unbehandelten (M0) bzw. M2 polarisierten MH-S 
Zellen konditioniertem Medium wiederum stimulierte die LA-4 Zellen die Expression von 
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Cxc3cl1 zu verstärken. Die prototypischen proinflammatorischen Zytokine TNF- und IL-1 
werden hauptsächlich von aktivierten Makrophagen sezerniert, und sind dafür bekannt 
während der akuten Entzündungsreaktion das Alveolarepithel inflammatorisch zu 
stimulieren.  In unserem in vitro Modell zeigte sich, dass LA4 Zellen die Expression von 
Ccl2, Cx3cl1 und Csf2 stark durch TNF-, wohingegen die Expression von Lcn2 
hauptsächlich durch IL-1 Gabe reguliert wurde.  
Diese Ergebnisse deuten darauf hin, dass im Alveolarepithel die Stimulation der Tgfb1 
und Csf2 Expression evtl. den Kontakt mit M1 polarisierten AM benötigt, wo hingegen 
Il6, Ccl2 und Lcn2 Expression auch durch von M1 AM freigesetzten, löslichen Faktoren 
stimuliert wird. Für die Induktion von Csf2 und Ccl2 ist von AM sezerniertes TNF- ein 
guter Kandidat und für Lcn2 entsprechend IL-1. Interessanter Weise war die epitheliale 
Cx3cl1 Expression unabhängig von IL-1 und wurde sowohl für pro- als auch anti-
inflammatorische Versuchsbedingungen beobachtet. Letzteres passt gut zu der 
angenommen Funktion des membrangebundenen CX3CL1 Zytokins als AM 
Chemoattractant, welches die Chemotaxis der AMs zu Orten der Pathogen-
Phagozytose (M1 Kondition) bzw. zur Efferozytose apoptotischer Zellen (M2 Kondition) 
steuern soll.  
 
2. Summary 
- 1 - 
 
2. Summary 
Alveolar macrophages (AM) play an important role during inflammatory lung diseases 
and provide the first line of defense of the lower airways. A major requirement for 
resident macrophages is their plasticity, which allows them to adapt according to the 
respective environment by modulating their state of activity, called polarization towards 
pro-inflammatory (classically activated, M1) or anti-inflammatory (alternatively activated, 
M2) phenotypes. The immunoproteasome is a specialized form of the proteasome which 
contains the three IFNγ-inducible catalytically active subunits: low molecular mass 
protein 2 (LMP2), multicatalytic endopeptidase complex-like 1 (MECL-1), and LMP7. 
They can replace their constitutive catalytic counterparts β1, β2, and β5, respectively. 
Apart from its major role in antigen presentation, immunoproteasomes have emerging 
functions in multiple innate and adaptive immune responses such as T cell survival and 
expansion, and Th17 differentiation. In view of the described key relevance of the 
plasticity of AMs for pulmonary host defense and homeostasis, combined with the 
impact of the immunoproteasome on cell-biological and immunological pathways, the 
study in chapter 1 was aimed to investigate the role of IP function in AM polarization. 
Here, we demonstrate that AMs can be polarized into M1 or M2 phenotypes after 
LPS/IFN-γ or IL-4 treatment, respectively. Both M1 and M2 AMs showed increased 
expression and activity of the IP subunits LMP2 and LMP7. The immunoproteasome 
kinetic study revealed increased expression and activity of LMP2, MECL-1, and LMP7 
during both M1 and M2 polarization of AMs. While the induction of M1 markers was not 
affected in LMP2 and -7-deficient AMs, the expression of M2 markers was clearly 
increased in LMP2 and -7-/- cells. Accordingly, we found that also phosphorylation of 
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AKT and STAT6, which are the most important signaling pathways involved in M2 
activation, were enhanced in LMP2 and -7-/- cells. In addition, our data showed that IRF-
4 expression, a crucial transcription factor driving M2 polarization, was upregulated in IL-
4/IL-13 treated AMs, and also further induced in LMP 7-/- cells. In further experiments, 
we figured out that the increased M2 markers and signaling is due to increased 
expression of IL-4Rα in LMP2 and -7-deficient AMs and confirmed our finding from 
knockout cells by using the LMP7 specific inhibitor ONX0914. Taken together, the study 
in chapter 1 demonstrated that LMP2 or LMP7 ablation enhances M2 polarization of 
AMs by modulating the IL-4 receptor expression, while it is dispensable for M1 
polarization. These results suggest that inhibition of individual immunoproteasome 
subunits might present a new avenue to modulate innate immunity in the lungs. 
The study of chapter 2 focused on the communication between polarized AM and 
epithelial cell. This study was aimed to identify the cellular factors derived from AMs 
which affect alveolar epithelial cells by using a trans-well co-culture and conditioned 
medium model. Here, we found that M1 polarized AMs enhanced the expression of 
several immune-related factors such as Il6, Tgfb1, Lcn2, Csf2, Ccl2 and Cx3cl1 in LA4 
cells, whereas conditioned medium from M1 AMs induced expression of Il6, Lcn2, Ccl2 
and Cx3cl1 in LA4 cells but not of Tgfb1 and Csf2. However, conditioned medium from 
M0 and M2 also markedly induced gene expression of Cx3cl1 in LA4 cells. The master 
pro-inflammatory cytokines TNF-α and IL-1β that are mainly secreted from macrophages 
have been well described to act on alveolar epithelial cells during acute inflammation. 
We found that mRNA expression of Ccl2, Cx3cl1 and Csf2 was strongly induced by 
TNF-α, whereas Lcn2 was strongly upregulated by IL-1β. These results indicated that 
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the induction of Tgfb1 and Csf2 expression in alveolar epithelial cells requires their 
contact with M1 polarized AM, whereas IL-6, CCL2 and LCN2 appeared already in 
alveolar epithelial cells and were further triggered by M1 AM released soluble factors. 
AM secreted TNF- seems to represent a plausible candidate inducing the expression 
of Csf2 and Ccl2, whereas the induction of Lcn2 is dependent on IL-1β. Interestingly, the 
epithelial expression of Cx3cl1 was independent of IL-1β, but its induction was observed 
in both pro- and anti-inflammatory experimental conditions. The latter finding matches 
well with the assumed function of this membrane-bound cytokine to attract AMs for 
pathogen clearance by phagocytosis (M1 condition) as well as efferocytosis of apoptotic 
cells (M2 condition). 
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3. Chapter 1: Immunoproteasome composition impacts alveolar macrophage 
polarization 
3.1. Introduction 
3.1.1. Macrophage Overview: Development, Location, and Functions 
Monocyte and macrophage development 
Macrophages represent a group of immune cells which are widely distributed throughout 
the body and all tissues. Monocytes, a subset of circulating white blood cells in 
vertebrates, constitute 2% to 10% of all leukocytes in the human body (1), and can 
further differentiate into macrophage under certain conditions. Monocytes are 
continuously generated from bone marrow hematopoietic stem cells via macrophage 
and dendritic cell precursors and common monocyte progenitor (2). It has been known 
for a considerable amount of time that the growth factor Csf-1 and also as recently 
reported the cytokine IL-34 are important for the development of this lineage (2, 3). 
Accordingly mice deficient in the Csf-1 growth factor exhibit lower amounts of blood 
monocytes (4). It has further been demonstrated that there are two subsets of 
monocytes which exist in the human blood. They are named CD14+CD16+ and 
CD14+CD16- monocytes and have differential responsibilities in the stimulation process 
(5). In mice, CSF1R+ monocytes are subdivided in distinct populations of 
LY6ChiCX3CR1midCCR2+ and LY6ClowCX3CR1hiCCR2− monocytes, which are thought to 
be equal to their human counterparts (6).  
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Fig 3.1: Scheme of monocyte and macrophage development. In the bone marrow, monocytes are 
continuously generated from hematopoietic stem cells (HSCs) via macrophage and dendritic cell (DC) 
precursor (MDP) and common monocyte progenitor (cMoP) intermediates. In the steady state, there are 
two functionally distinct monocytes called LY6C
hi
 and LY6C
low
 subsets circulating in blood vessel to 
form a developmental continuum (BOX 1). Macrophage-like LY6C
low
 cells patrol the endothelial surface 
and coordinate its repair by recruiting neutrophils. LY6C
hi 
monocytes are rapidly recruited to sites of 
inflammation and sites of tissue remodeling, where they extravagate and can give rise to monocyte-
derived DCs and monocyte-derived macrophages. Copied from (6). 
3.1.2. The overview of tissue macrophage location and origin  
Tissue-resident macrophage populations are found in the majority of tissues in the body 
including microglia in the brain, alveolar macrophages in the lung, and Langerhans cells 
in the skin and Kupffer cells in the liver (7). They are unique phenotypes according to 
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their distinct micro-niches that are extremely heterogeneous, which makes them exhibit 
tissue specific functions and adapt to the tissue environment in which they reside (7). 
Tissue-resident macrophages were firstly recognized as phagocytic cells for invading 
pathogens. They are considered to be the frontline of tissue defense (8). Intensive 
studies revealed that tissue macrophages play an essential role in immune response 
and inflammation, such as the clearance of microbes and necrotic and apoptotic cells, 
initiation of the innate immune response to infection and the resolution of inflammation 
(9). Studies on the role of the specific function of tissue macrophage in each 
inflammatory related disease according to its site will help us to understand their 
pathogenic contribution to disease. For instance, Kupffer cells (KC), also known as 
Browicz-Kupffer cells, reside within the lumen of the liver sinusoids (10),  which  enable 
them be easily exposed to toxic components arising in the blood such as bacterial 
endotoxins, ethanol and toxic substances from the gut (11, 12). Therefore, Kupffer cells 
have been reported to be involved in many liver diseases including acute liver injury, 
alcohol-related liver disease and liver infections (13).  Microglia, another type of resident 
macrophage reside in the brain and spinal cord, and thus is believed to play the crucial 
role in brain infectious disease, Alzheimer's disease, Parkinson's disease, multiple 
sclerosis and several psychiatric disorders (14, 15). 
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Fig 3.2: Scheme of localization of tissue macrophage.  Copied from (16) 
It has been well documented that bone marrow hematopoietic stem cells (HSCs) give 
rise to circulating monocytes, which can differentiate in tissues into macrophages. 
However, a recent study showed that the mouse embryo yolk sac is a sufficient source 
of specific tissue macrophage subtypes in the liver, skin and central nervous system 
(CNS) in the absence of HSCs (17). 
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Fig 3.3: Scheme of origin of tissue macrophages. At embryonic day 7.5 (E7.5)–E8.0, a process, called 
primitive hematopoiesis, is a transient early wave of myeloid cell development. At this period, in blood 
islands of the yolk sac, cells with stem cell potentials develop. Their progeny erythromyeloid progenitors 
(EMPs) further differentiate and populate several tissues, including the brain, where they become tissue 
macrophages that potentially have longevity and a high capacity for self-renewal. Taken from (18). 
Alveolar macrophages (AM) 
Pulmonary macrophages are considered to exist within at least two anatomically distinct 
compartments. The alveolar macrophage (or dust cell) predominantly set in the airspace 
of alveoli where they are in close contact with the respiratory epithelium. They act as the 
lung’s first defense line against inhaled pathogens and environmental pollutants (19). 
The plasticity of alveolar macrophages is required to adapt to a unique airway 
microenvironment (17), which finally causes alveolar macrophage to be an unusual 
phenotype in many respects compared with other lung resident macrophages (17). The 
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interstitial macrophage, on the other hand, resides in the lung parenchyma (20). 
Although these cells share many common features of alveolar macrophage, in mice, 
alveolar macrophages are easily distinguished from interstitial macrophages by their 
unusual phenotype (Table1) (17).  
Surface marker Interstitial macrophage Alveolar macrophage 
CD11b Intermediate expression Not expressed 
CD11c Not expressed High expression 
CD14 Intermediate expression Low expression 
CD200R Intermediate expression High expression 
DEC205 Expression unknown Intermediate expression 
F4/80 Low expression Low expression 
Mannose receptor Intermediate expression High expression 
MHC class II Intermediate expression Low expression 
SIGLEC-F Not expressed High expression 
         
Table 1: The specific phenotype of mouse macrophages from different sites. Adapted from (17). 
In addition, it has been found that alveolar macrophages have many properties of 
dendritic cells (DC) (21). For example, they have a better antigen-presenting capability 
than peritoneal lavage-derived macrophages (PLM) (21). The dendritic cell marker 
CD11c has also been found to be more highly expressed in the alveolar macrophage 
compared to other macrophages (22).  
It has been controversial for many years whether AMs are derived from their blood 
precursor monocytes. Newly published studies have indicated that AMs develop from 
fetal monocytes rather than  arise from circulating blood monocytes and adopt a stable 
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phenotype shortly after birth in response to instructive cytokines, and then self-maintain 
throughout life (18, 23, 24). However, the signals and molecular mechanisms that drive 
AMs and when such signals are provided are not yet fully understood. A recent study 
has shown that the CSF2 induced expression of the nuclear receptor PPAR-γ is 
essential for the differentiation of AMs from fetal monocytes. (24, 25). 
 
Fig 3.4: localization of alveolar macrophage in the alveolus. Alveolar macrophages are localized on the 
top of alveolar type I cell which is surrounded by the alveolar fluid. The main content of alveolar fluid is 
surfactant which are secreted by the alveolar type  II cells.  Adapted from (26). 
3.1.3. Macrophage functions 
The phagocyte is a type of leukocyte that protects the body by engulfing and ingesting 
harmful foreign particles, bacteria, and dead or dying cells (27, 28). Professional 
phagocytes include many types of leukocytes (such as neutrophils, monocytes, 
macrophages, mast cells, and dendritic cells). Macrophages are one type of phagocytes, 
which are responsible for recognition, engulfing and killing of pathogens and apoptotic 
cells (29). Another essential role of macrophages is alerting the immune system to the 
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presence of invaders and immune disorders. In addition, macrophages are able to repair 
the tissue injuries (30). 
3.1.3.1. Phagocytosis 
Monocytes and macrophages are recruited to the site of injury, inflammation and 
infection. When macrophages come into contact with a pathogen or apoptotic cell, 
macrophages use a mechanism called phagocytosis to engulf the pathogens into cells. 
Phagocytosis is a specific form of endocytosis involving the vesicular internalization of 
solids such as bacteria and environmental particles. Phagocytosis is derived from the 
Greek words 
 "phagein" meaning “to eat” and is the word used to describe the engulfing and 
destruction of pathogens. Phagocytosis was first discovered by Élie Metchnikoff in 1882 
(31, 32). Upon engulfment, a vesicle called a phagosome is formed around the microbe 
by the cell membrane which then fuses with a lysosome specialized vesicle that contains 
digestive enzymes to destroy the pathogens (33, 34). Some macrophages act as 
scavengers, removing dead or necrotic cells while others provide host immunity by 
engulfing microbes (35, 36). Most macrophages can live for several months and can kill 
hundreds of different bacteria before they die. In this process, macrophages provide a 
non-specific or innate immunity. The precise process of phagocytosis depends upon the 
particle being internalized, its size and whether it controls its own fate (37). In broad 
terms, the uptake process usually requires receptors which include Fc-receptors, CD44, 
MARCO and CD36 in order to collect around the particle (38-41), to archive signaling to 
promote membrane extension and polymerization of the underlying actin cytoskeleton, 
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and subsequent maturation of the internalized vacuole (the phagosome) to fuse with 
lysosomes and initiate particle degradation (42).  
 
Fig 3.5: A bacterium phagocytosed by a macrophage. Binding of phagocyte surface receptors 
causes the internalization of bacterium into phagosome. The phagosome ingested with bacterium is then 
fused with the lysosome, forming a phagolysosome and leading to degradation of bacterium. Taken from 
(http://en.wikipedia.org/wiki/Phagocyte) 
3.1.3.2. Bridging Innate and Adaptive Immunity 
The immune system is typically divided into two categories: innate and adaptive 
although these distinctions are not mutually exclusive (43). Innate immunity refers to the 
nonspecific defense mechanisms that occur immediately or within hours of the 
appearance of pathogens. The macrophage, being the first line of defense against many 
common pathogens, is thought to be the crucial player of the innate immune system 
(44). In order to recognize pathogens, pattern recognition receptors expressed on 
macrophages are able to distinguish between self and nonself, which then leads to the 
activation of an immune signaling pathway and production of immune mediators such as 
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the cytokines and antimicrobial peptides (45). On the one hand, cytokines can amplify 
the immune response locally by binding to their receptors, on the other hand they can 
recruit lymphocytes which are a sign of involvement of the adaptive immunity (46). This 
is how macrophages alert the immune system to microbial invasion. In addition, 
macrophages can process and present foreign antigens as well as dendritic cells to a 
corresponding T cell. The antigen being displayed is attached to an MHC class II 
molecule, which acts as a signal to activate T cells (47). Moreover, T cells also stimulate 
B cells to generate specific antibodies to each antigen. This "signature" antigen is also 
remembered by T cells and B cells, which allow them to target the antigen again in 
future (48). Therefore, the macrophage is one of the crucial white blood cells that are 
able to bridge innate and adaptive immunity. 
3.1.3.3. Macrophage activation and polarization  
The macrophage is a particularly dynamic cell during anti-pathogens immune 
responses, inflammation, resolution and tissue wound healing (49, 50). Under such 
conditions, macrophages of different origin, being monocytes or tissue macrophages 
can acquire distinct functional phenotypes depending on their surrounding 
microenvironment. Two well-studied polarized subsets have been established according 
to their functions and distinct gene expression profiles, which are the classically 
activated macrophages (M1 macrophages) and alternatively activated macrophage (M2 
macrophages)(51). M1/M2 paradigms are analogized with Th1 (T helper 1)/Th2 (T 
helper 2) type immunes responses. It is worth noting that inducible expression of iNOS 
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and arginine Arginase1 were well described as markers for respective characterization 
of M1 and M2 macrophages (51-54).  
The M1 polarized macrophage, whose prototypical activating stimuli are IFNγ and LPS, 
and alternatively activated macrophages (or M2) are further subdivided into in M2a 
(stimulation of IL-4 or IL-13), M2b (immune complexes in combination with IL-1beta or 
LPS) and M2c (IL-10, TGF-β or glucocorticoids). M1 macrophages show strong anti-
microbe properties with high production of pro-inflammatory cytokines (TNF-a, IL-1b, 
and IL-12) and antimicrobial effectors (nitric oxide and defensins), which are mainly 
presented during acute infection and inflammation (50). M2 polarized macrophages are 
believed to play a crucial role in tissue repair and resolution of inflammation due to their 
high phagocytic clearance of apoptotic neutrophils and the secretion of anti-inflammatory 
cytokines (e.g. IL-10)(51). M2a macrophages induced by IL-4 or IL-13 trigger a Th2 type 
like immune response, and are involved in anti-infectious responses to parasites e.g. 
against Helminth Parasites (55). In addition, new evidence indicates that M2 
macrophages have a pro-fibrotic role in fibrosis (56). M2b macrophages are considered 
immunity regulation and are induced by LPS, IL-1 and immune complexes. Besides IL-
10 they also produce IL-1, IL-6 and TNF-a. M2c macrophages are induced by IL-
10/TGF-β and also exhibit anti-inflammatory functions (57). It has also been shown that 
the M2c but not M2a macrophages induce regulatory T cells (Tregs) from CD4+CD25- T 
cells in vitro and are more effective than M2a macrophages in protecting against tissue 
injury (57). Moreover, thorough studies have evidenced that polarized macrophages 
control immune responses and  inflammation by a chemokine repertoire that recruits 
other immune cells; for instance, M1 macrophages express the chemokines CXCL1, 
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CXCL2, CXCL3, CXCL5, CXCL9, and CXCL10 and CCL2, CCL3, CCL4,CCL5, CCL11, 
and M2 macrophages increase expression of CCL2, CCL17, CCL22, and CCL24 (58, 
59) 
 
Fig 3.6: Scheme of M1 (classical) and M2 (alternative) macrophage polarization. Several cytokines 
and chemokines are involved in the classical and alternative activation of macrophages. Monocytes get 
differentiated into macrophages which in turn polarize to M1 type on exposure to LPS or IFNγ. Various 
signals define the different forms of alternative activation of macrophages. IL-4 or IL-13 induces M2a 
subtype; IL1β or LPS or immune complexes induces M2b macrophages; and IL10 or glucocorticoids 
results in M2c macrophages. Taken from (http://cdn.intechopen.com/pdfs-wm/46529.pdf).   
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3.1.4. Transcriptional networks of macrophage polarization 
A variety of studies have been carried out to understand the signaling pathways, 
transcription factors, and epigenetic regulation during macrophage polarization. By using 
the technique of mouse genetic deletion of genes in macrophages, a number of 
pathways were identified to be involved in molecular mechanisms of macrophage 
polarization. In the following sections, the key transcription factors are discussed for their 
roles in a polarized macrophage phenotype. 
 
Fig 3.7: Signaling pathways in M1 and M2 macrophage polarization. IFNγ, LPS and CSF2 or 
Fungi/helminths, CSF1 and IL-4/IL-13 respectively induce the M1 or M2 polarization. The main genes 
that are characteristic of either the M1 or the M2 polarized state are also shown. The main marker genes 
used for M1 characterization are Nos2, Il12b, Ciita and Il6, and Arg1, Chi3l3, Retnla and Mrc1 are used 
as M2 marker. The main transcription factors involved in M1 polarization are STAT1/STAT2, STAT5, 
IRF5, NF-κB, AP1 and IRF3, IRF4, and PPARγ, C/EBPβ, STAT6 and mTOR for M2. Taken from (60). 
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3.1.4.1. The NF-κB /STAT1 signaling axis 
Polarized (M1) macrophages show increased anti-microbial activity by enhanced 
expression of NOS2, increased MHC class II expression, and increased secretion of IL-
12 which promotes the Th1 immune response (61). IFNγ-mediated Janus kinase–signal 
transducer and activator of transcription (JAK–STAT) are supposed to regulate 
transcription of those genes (62), which are characterized by IFNγ receptor triggered 
JAK-mediated tyrosine phosphorylation and subsequent dimerization of STAT1 which 
binds to IFN gamma-activated sequences in the promoters of the M1 markers gene (60). 
LPS is often a co-stimulus of IFNγ for M1 polarization as it binds to the Toll like receptor 
TLR4 and leads to activation of nuclear factor kappaB (NF-κB) which induces 
expression of pro-inflammatory cytokines such as Tnf, Il1b, Il6 and Il12. The NF-κB p65 
and p50 heterodimer complexes with the inhibitory protein IκBα in the cytosol but is 
released after the phosphorylation of IκBα by IκB kinase (IKK) and translocated into the 
nucleus where it binds to the NFκB response element (TRE) (63). In addition, LPS 
induces the production of IFNβ which in turn binds to the IFNα/β receptor and triggers 
the formation of STAT1–STAT2 heterodimer to induce the M1 signature gene 
expression, such as Nos2, Tnf and Il12b. Therefore, it is clear that both NF-κB and 
STAT1 activity is crucial for M1 macrophage polarization (64). It has been shown that 
STAT1-deficient mice have severe malfunctions in immunity, which causes them to be 
hypersensitive to bacterial and viral pathogens infection (65). 
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3.1.4.2. The JAK–STAT6-SOCSs signaling pathway 
Cytokines IL-4 and IL-13 have been well established to induce M2a polarization of 
macrophages. They are supposed to bind to the interleukin 4 receptor alpha (IL-4Rα) 
and interleukin13 receptor alpha 1 (IL-13Rα1) and lead to phosphorylation of JAK1 and 
JAK3 to further trigger the phosphorylation of STAT6. Following homo-dimerization, 
STAT6 translocate into the cell nucleus where it recruits the IRF4 and initiates the 
transcription of M2 markers genes, including arginase 1 (Arg1), macrophage mannose 
receptor 1 (Mrc1; also known as Cd206), resistin-like-α (Retnla; also known as Fizz1) 
and chitinase 3-like 3 (Chi3l3; also known as Ym1). Additionally, STAT6 also induces 
expression of the transcription factor PPAR-γ, which acts in synergy with STAT6 to 
promote the expression of M2-specific genes and macrophage polarization (66, 67). It 
has been investigated that mice harboring the specific knockout of the Il4ra and STAT6 
are not able to polarize to M2 macrophages which leads to a disorder in TH2 cell-
mediated inflammation (66). Suppressors of cytokine signaling (SOCS) are important 
regulators of LPS and cytokine responses. They are the endogenous inhibitors of STAT 
proteins, which inhibit the JAK-STAT pathway by negative feedback of cytokine 
signaling. Corresponding studies have reported that SOCS1, -2, and -3 are induced in 
response to cytokine stimulation, and the corresponding SOCS proteins inhibit cytokine-
induced signaling pathways (68). SOCS family members modulate signaling by several 
molecular mechanisms, which include inactivation of the Janus kinases (JAKs), blocking 
the binding of the signal transducers of transcription (STATs) to receptors, and 
ubiquitination of signaling proteins and their subsequent targeting to the proteasome 
(68). Recent studies have suggested that SOCS2, and SOCS3 differentially contribute to 
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macrophage M1 and M2 polarization (69). It has been demonstrated that there is a bias 
toward M1-macrophage polarization in SOCS2-deficient mice, whereas SOCS3-deficient 
macrophages express surface markers associated with M2-macrophage polarization 
(69, 70). 
3.1.4.3. IFN Regulatory Factors (IRF-3, IRF-4 and IRF-5) 
Interferon regulatory factors are proteins which regulate transcription of interferons. In 
mammals, the IRF gene family consists of nine members: IRF-1, IRF-2, IRF-3, IRF-4, 
IRF-5, IRF-6, IRF-7, IRF-8, and IRF-9 (71). IRFs are also involved in many immune 
processes, including anti-bacterial and virus immunity, Th1-cell responses, dendritic cell 
development, and inflammation (72). IRFs are also found to play a crucial role in the 
regulation of macrophage polarization. It has been suggested that IRF-3 is associated 
with inflammatory microenvironments and contributes to the polarization toward a M1 
macrophage phenotype. Two adaptors, MyD88 and TRIF, mediate the signaling 
downstream of TLR4 (73, 74). The signaling through the TRIF adaptor pathway 
activates IRF-3 which leads to the secretion of type I interferons, such as IFN- and 
IFN-β (73, 75). Then, these type I interferons induce the activation of the transcription 
factor STAT1 and the transcription of M1 marker genes such as CXCL9 and CXCL10 by 
binding to the type I interferon receptor (IFNAR) (73, 76). Another recently described 
interferon regulatory factor in the regulation of M1 polarization is IRF-5. Previous studies 
have shown that IRF-5 is needed for the optimal expression of IL-12 and pro-
inflammatory cytokines in mice (77). CSF2-polarized M1 macrophages exhibited up-
regulated expression of IRF-5. M1 markers genes expression were increased by the 
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overexpression of IRF-5 and inhibited slightly by IRF-5 interfering RNA (siRNA). The 
capability of IRF-5 in regulating these M1 gene expressions is due to the direct 
recruitment of IRF-5 to gene promoters such as Il12b, but it represses transcription of 
Il10, probably also by binding to an ISRE in the gene promoter which has to be further 
investigated (78). 
IRF-4 is described as a lymphocyte-specific transcription factor of the IRF family, and is 
a negative regulator of Toll-like-receptor (TLR) signaling which is central to the activation 
of the innate and adaptive immune systems (79). However, recent studies have shown 
that IRF-4 was able to specifically regulate M2 macrophage polarization in response to 
IL-4 and parasites or the fungal cell-wall component chitin. The regulation of 
macrophage polarization by IRF-4 involves histone demethylase JMJD3 which could 
remove an inhibitory histone modification called H3K27me3. Cells devoid of JMJD3 are 
not able to polarize into the M2 phenotype while not having a role in regulation of M1 
macrophages (80).   
3.1.4.4. PI3K/AKT/mTOR pathway 
The PI3K/AKT/mTOR pathway is an intracellular signaling pathway which is important in 
apoptosis and hence cancer (81). Moreover, it has been recognized that this pathway 
also has broad roles in innate and adaptive immune cells, including neutrophils, 
monocytes, macrophages and dendritic cells as well as B and T lymphocytes (82). It has 
been shown that the PI3K/mTOR pathway is activated by a broad array of different 
stimuli via specific receptors, including the BCR, TCR, cytokine receptors (eg, interleukin 
2), insulin receptor, insulin-like growth factor I receptor, but also TLRs (82). LPS and IL-4 
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used to induce the M1 and M2 macrophages respectively have both been shown to 
induce phosphorylation of AKT and PI3K which further leads to activation of mTOR. 
Hence, in recent years, scientists have become increasingly interested in examining its 
role in regulation of macrophage polarization. AKT (also known as PKB) is a family of 
three serine/threonine protein kinases (AKT1, AKT2, and AKT3) that regulate many 
cellular functions. A study has unexpectedly shown that AKT2−/− macrophages are 
hypo-responsive to LPS stimulation, exhibiting the opposite phenotype to AKT1−/− 
macrophages (83). Moreover, AKT2−/− macrophages show an M2 phenotype attributed 
to reduced expression of miR-155 which targets C/EBPβ that is a key regulator of M2 
polarization (83). mTOR was first named as the mammalian target of rapamycin, that 
integrates both intracellular and extracellular signals, and serves as a central regulator 
of cell metabolism, growth, proliferation, survival and the immune response (84). Newly 
published studies have indicated an existence of an mTORC1-AKT regulatory loop in 
the IL-4 signaling pathway in which the receptor engagement of the IRS/PI3K/AKT 
pathway leads to mTORC1 activation that in turn attenuates AKT signaling. Genetic loss 
of either TSC1 or TSC2 leads to constitutive mTORC1 activation. It has been 
demonstrated that TSC1−/− macrophages have a marked defect in M2 polarization in 
response to IL-4, while the inflammatory response to LPS is enhanced (85).  
3.1.5. The role of alveolar macrophage polarization in chronic lung diseases 
The lung is a major site of continuous immune reactions as it encounters various foreign 
particles and antigens entering the respiratory system. Alveolar macrophages are 
among the most abundant immune cells in the respiratory tract, and they are a unique 
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type of mononuclear phagocytes that populate the surface of the lung in steady state. 
They form the first line of defense against pathogens invading the alveolar space. 
Although alveolar macrophages exhibit unique properties compared with other resident 
macrophages, they could also polarize into distinct phenotype of M1 and M2 
macrophage in vitro (86). When exposed to a specific microenvironment, macrophages 
acquire either M1- or M2-polarized phenotypes associated with inflammation and tissue 
remodeling, respectively. With the dramatic changes of the micro-environment during 
chronic inflammatory lung diseases, the alveolar macrophage accordingly polarizes into 
the characteristic M1 or M2 phenotype. A number of studies have shown that alveolar 
macrophage polarization has a crucial role in the pathogenesis of chronic lung 
inflammatory diseases including chronic obstructive pulmonary disease (COPD), asthma 
and idiopathic pulmonary fibrosis due to their contribution in the initiation, regulation and 
termination of inflammation.  
3.1.5.1. Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung 
function decline and an abnormal inflammatory response in the airways, and is mainly 
caused by cigarette smoke. The accumulation of immune cells including macrophages, 
neutrophils, CD8+ -lymphocytes and B-cells has been proven to be associated with the 
severity of COPD (87). Alveolar macrophages play a critical role in the pathophysiology 
of COPD and are a major target for an anti-inflammatory therapy in future. Alveolar 
macrophages from COPD patients have an increased baseline and stimulated secretion 
of inflammatory proteins, including certain cytokines, chemokines, reactive oxygen 
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species and elastolytic enzymes, which together could contribute to all of the 
pathophysiological features of COPD (88). With the intensive studies about macrophage 
polarization in both in vivo and in vitro, hence, the role of the distinct macrophage 
polarized phenotypes in COPD gained the attention of immunologists and 
pulmonologists. Based on studies with COPD patients, initially M1 polarization was 
expected to play a crucial role in COPD (89). It is well known that thousands of 
compounds presented in cigarette smoke, including the LPS as a natural contaminant of 
tobacco smoke can polarize macrophages into M1 in vitro, characterized by high 
expression of iNOS (90). Previous studies have already proven that iNOS is induced in 
the lungs of COPD patients (91). Moreover, many studies have shown that COPD 
patients showed higher concentrations of the pro-inflammatory M1 cytokines, IL-1β, IL-6, 
and TNF-α (92) which are partially released from alveolar macrophages. MMP9, a 
protease of the matrix metalloproteinase (MMP) family, is suggested to be involved in 
the breakdown of the extracellular matrix in COPD (93). M1 macrophages have also 
been found to secrete MMP9, which presumably facilitate macrophage migration during 
inflammation (94). All of these studies have indicated the essential role of polarized M1 
macrophages in COPD pathogenesis. However, a study by Lisette Kunz showed 
contradictory results. They showed that the percentage of macrophages with M2-type 
characteristics is significantly higher in the BAL from ex-smokers than in current 
smokers with COPD but this increased anti-inflammatory phenotype is not necessarily 
accompanied by a decrease in inflammatory parameters (89). Therefore, this study 
indicates the important role of M2 macrophage polarization in COPD. Alternatively 
activated M2 was induced by the Th2 –biased cytokines IL-4 and IL-13. It have been 
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demonstrated that IL-13 were induced in COPD patients and was thought to contribute 
to inflammation, emphysema, and mucus metaplasia (95). This also raises a possibility 
that IL-13 overexpression induces M2 polarization in COPD. MMP12, another type of 
matrix metalloproteinase, is well known for its role in COPD and emphysema progress 
(96). Previous studies showed that MMP12 could be induced in IL-4-stimulated M2 
macrophages (97). In summary, some evidence indicates the role of M2 activation in 
COPD, which may contribute to the development of COPD. So far, no studies have been 
conducted to exactly characterize the phenotype and role of M1 and M2 in COPD.  
3.1.5.2. Asthma 
Asthma is a complex lung disease, which is characterized by airway inflammation and 
airway hyperresponsiveness (AHR). It has been well documented that alveolar 
macrophages play a crucial role in the development and progression of asthma (98). 
Asthma is a chronic inflammatory disease with increased influx of inflammatory cells in 
the lungs along with a prominent Th2 cytokine signature (99). Among inflammatory cells, 
macrophages are the most abundant leukocytes found in the airspaces, which suggest 
that they have an important role in fighting against pathogens and airway remodeling 
and eosinophilic inflammation in asthma (100).  
Firstly, the pro-asthmatic role of M1 macrophages has been investigated in clinical and 
then in experimental asthma. On the one hand, it has been shown that asthmatic 
macrophage is insufficient to fight against with microbe infections in the respiratory tract 
(101), which indicate the dysfunction of M1 activation, on the other hand, asthmatic 
macrophage are able to release M1 related pro-inflammatory mediators such cytokines 
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and nitric oxide (102, 103). For instance, recent investigations revealed that the 
generation of ATP and uric acid upon airway exposure to allergens leads to the release 
of the IL-1β from alveolar macrophages through activation of an inflammasome complex 
which can cleave pro-IL-1β to mature IL-1β together with caspase-1. IL-1β production 
could further lead to the enhanced Th17 cell differentiation which contributes to the 
control of allergic asthma (104). Moreover, nitric oxide, as one of main products of M1 
polarized macrophage, is believed to amplify lung injury during asthma due to DNA 
damage, inflammation, and increase mucus production in a murine model of 
allergen(105, 106). Furthermore, it has been well documented that LPS is involved in the 
initiation of asthma, and both the level of LPS and IFN- used for M1 induction in vitro 
increased significantly in severe asthmatic patients (107, 108). Thus, alveolar 
macrophage polarization toward the M1 subset can promote the development of 
asthmatic disease. 
In the context of the Th2 like immune response in asthma, Th2 cytokines IL-4 and IL-13 
were found to be abundantly expressed in asthmatic lungs (109), and therefore it is not 
surprising that alveolar macrophage from asthma patients also expressed M2 markers. 
Such as elevated levels of chitinase family members have been found in the serum and 
lungs of patients with asthma (110). In addition, it has been shown that asthmatic 
macrophages exhibit higher levels of M2 markers, including mannose receptor and 
transglutaminase 2 (111, 112). In other studies, it has been found that sequence 
variations in the MRC1 gene correlated with asthma severity (113). M2 cells that 
secreted FIZZ1 (a resistin-like molecule-α) were found to be overexpressed in asthma. 
Jun Fei Wang has found that FIZZ1 plays a role in the early stages of airway remodeling 
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in asthma by increasing the expression of α smooth muscle actin (α-SMA) and type I 
collagen through the activation of the PI3K/AKT signaling pathway in asthma (114). 
Moreover, increased expression of Th2 chemokines CCL17 and CCL22 in asthma have 
been reported (115). Previous work has demonstrated that CCL17 and CCL22 are 
responsible for the recruitment of CCR4+T lymphocytes into asthmatic tissue which are a 
major source of TH2 cytokines IL-4 and IL-13 (116). Newly published research has 
indicated that there is an overexpression of CCL17 in alveolar macrophages of 
asthmatic patients, which correlated significantly with sputum eosinophilia (117). 
Therefore, this research again supports the important role of M2 phenotype in asthma 
pathogenesis. 
In summary, complex cytokine networks are involved in the pathophysiological progress 
of asthma because of the multifactorial nature of asthma, which also give rise to the 
reason of involvement of both M1 and M2 macrophages in asthma. Therefore, future 
work should help us to understand how the balance between M1 and M2 macrophages 
contribute to this complicated chronic lung inflammatory disease. 
3.1.5.3. Pulmonary fibrosis 
Pulmonary fibrosis is a lung disease that is resistant to treatment and carries a high 
mortality rate. It is characterized by the progressive and irreversible destruction of the 
lung architecture caused by scar formation that ultimately leads to lung malfunction, 
disruption of gas exchange, and death from respiratory failure (118). Idiopathic 
pulmonary fibrosis (IPF), a particularly severe form of pulmonary fibrosis with unknown 
cause, primarily occurs in older adults, and is associated with the histo-pathologic 
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pattern of usual interstitial pneumonia (UIP) (119). It has been suggested that alveolar 
macrophages are integrated into all stages of the fibrotic process, which may be due to 
its key role in fibroblast recruitment, proliferation, and activation (120). Additionally they 
are involved in the recruitment of inflammatory cells to sites of tissue injury by releasing 
chemokines and degrading ECM components by secreted specific matrix 
metalloproteinases (121). Furthermore, it is well known that pro-fibrotic mediators, 
including TGF-β1 and PDGF that induce the proliferation and activation of collagen-
secreting myofibroblasts (119), are released by alveolar macrophages. During 
pulmonary fibrosis the plasticity of alveolar macrophages is needed to allow them to be 
able to polarize in each distinct phenotype in response to the dynamic micro-
environment changes in airs pace. So far, there are no substantial studies about the role 
of M1 macrophages in pulmonary fibrosis. But according to previous research, it is well 
feasible that M1 alveolar macrophages contribute to fibrosis particularly in the initial 
phases of the disease. In the earliest stages of tissue damage, epithelial cells or 
endothelial cells may release inflammatory mediators that can promote the M1 
macrophage polarization. Once polarized toward M1, macrophages produce TNF-α, IL-
1β, and oxygen radicals. Many studies have indicated that these inflammatory cytokines 
and oxygen radicals are associated with development of fibrosis with their ability to 
amplify the inflammatory response and cause further tissue damage (94).  
Due to the importance of the Th2 inflammatory responses in the development of 
pulmonary fibrosis, there are many studies reporting on the role of M2 macrophage 
polarization in the fibrotic phase of lung fibrosis. It has been demonstrated that IL-13 and 
IL-13R are highly expressed in IPF patients correlating with disease severity (122). 
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Thus, it is not surprising that M2 macrophages were found to be increased in BALF of 
IPF patients (94, 123, 124). M2 macrophages secrete a number of inflammatory and 
pro-fibrotic mediators, among them Th2 chemokines such as CCL17, CCL18 and 
CCL22 that have been reported to be associated with fibrosis development by recruiting 
CCR4+ T cells (123). It has been demonstrated that serum CCL18 concentrations have 
a predictive value in IPF and may be a useful tool in the clinical management of patients 
with IPF (125). In a bleomycin induced mouse fibrosis model, one study showed that 
CCL17 is elevated in bleomycin treated mice compared with the control group, and that 
application of a CCL17 neutralizing antibody attenuated fibrosis and pulmonary 
inflammatory cell numbers (126). Other M2 markers have also been shown to be 
increased in IPF such as galectin-3. It has been reported that galectin-3 contributes to 
the transforming growth factor-β1-driven lung fibrosis and that TD139, an inhibitor of 
galectin-3, attenuated the late-stage progression of bleomycin caused lung fibrosis by 
inhibiting TGF-β–induced β-catenin activation in vitro and in vivo (127). However, there 
are also some contradictory findings suggesting that M2 macrophages could be anti-
fibrotic by suppression and resolution of fibrosis and uptake of ECM components. One 
study has shown that mice lacking arginase-1 in M2 macrophages have signs of 
unresolved inflammation and fibrosis (128). Uptake of these components is mediated by 
different mannose receptors which are known as M2 markers, and mannose receptor 
has shown to attenuate fibrosis in different models (129). 
To summarize, both M1 and M2 alveolar macrophages are important cells in the 
pathogenesis of fibrotic lung diseases. M1 macrophages are thought to be more 
important in the initial inflammatory phase while M2 macrophages contribute mainly to 
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the fibrotic phase. Therefore, understanding how these two phenotypes contribute to 
different phase of pulmonary fibrosis is very important in understanding the development 
of this disease. 
3.1.6. Protein degradation by the proteasome 
In 2004, the Nobel Prize in Chemistry was awarded to the scientists for their discovery of 
the ubiquitin-proteasome mediated protein degradation. The ubiquitin-proteasome 
system (UPS) is the primary means by which cellular proteins are degraded and is a 
highly regulated system for the elimination of misfolded or damaged proteins as well as 
proteins whose activity is acutely regulated by signaling pathways (130). Therefore, this 
system has been reported to play a central role in almost all the cellular processes 
including cell proliferation, transcriptional regulation, apoptosis, immunity, and 
development (131). The core structure of this system is the 26S proteasome, a dynamic 
multi-subunit proteolytic complex within the cell, which functions as the key enzyme for 
non-lysosomal protein degradation (132).  
Ubiquitin (Ub) is a small protein (76-residue) that is evolutionarily highly conserved in all 
eukaryotes (130). The initial signal for the degradation of the targeted protein is the 
selective binding of ubiquitin to the target proteins. The conjugation of Ub to a target 
protein is a three step process that begins with a high energy thioester linkage with an 
Ub-activating enzyme, also called an E1. Afterwards, this E1 “activated” Ub is then 
delivered to the active-site cysteine of an Ub-conjugating enzyme (E2). In step three, the 
addition of ubiquitin to the protein substrate is catalyzed by one of many Ub-protein 
ligase (E3) s - a diverse group of proteins (133). The high specificity and selectivity of 
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the UPS system lies in the diversity of E3s different ubiquitin-protein ligase that can 
recognize a specific substrate (133). 
 
Fig 3.8: The schematic diagram showing ubiquitylation of substrate protein and its subsequent 
degradation by the 26S proteasome complex. An ubiquitin activating enzyme (E1) first forms a 
thioester bond with ubiquitin and then binds to an ubiquitin conjugating enzyme (E2). Subsequently, in the 
presence of an ubiquitin ligase enzyme (E3), the carboxy-terminus of ubiquitin forms an isopeptide bond 
with a K residue on target protein. The 26S proteasome recognizes, unfolds and degrades the 
polyubiquitylated-target protein into small peptides. Ub, ubiquitin. Taken from (134). 
3.1.6.1. Structure of the proteasome  
The proteasome is a self-compartmentalized protease. It carries out proteolytic activities 
deep within its interior, which means that it requires the appropriate features to gain 
access to the central proteolytic chamber. Once the delivery of the target protein to the 
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proteasome after complicated ubiquitin modification mediated by the chaperones and 
shuttling factors has taken place, most of proteasome actions are regulated by the 
regulatory subunit which  feed substrates to the inner protease sites (135). 
The 26S proteasome complex is a non-lysosomal proteolytic machine that consists of a 
20S core particle (CP) and a 19S regulatory particle (RP), the latter of which can be 
further subdivided into lid and base sub-complexes. The 20S CP confers the proteolytic 
activities of the proteasome, whereas the 19S RP shows an ATP-dependence and 
specificity for ubiquitin protein conjugates (132). The 20S CP resembles a cylinder 
composed of four rings (two α and two β rings). Both of each α and β rings are 
composed of seven different α components (α1–α7) or β components (β1–β7) to form a 
β ring. In the β ring, three of the seven β-components were proven to be catalytically 
active, and are named by their substrate specificities: chymotrypsin-like (β5), trypsin-like 
(β2), and caspase-like (β1) (134). The chymotrypsin-like activity cleaves proteins leaving 
hydrophobic residues, while the trypsin and caspase-like activities cleave, leaving basic 
and acidic residues, respectively (134). With the help of the 19S RP, the target proteins 
are delivered into the catalytic chamber of the 20S CP. It has been proven that the 19S 
is the proteasome regulatory particle (RP) responsible for recognition and processing of 
ubiquitinated substrates. Established as a highly dynamic proteasome activator, the RP 
has a large number of both permanent and transient components with specialized 
functional roles that are critical for proteasome function (136).  
The 26S proteasome, also named constitutive proteasome, is found in most cells. In 
contrast to the constitutive form of proteasome, there is an inducible proteasome called 
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immunoproteasome (IP) which is tissue-specific and abundant in immune-related cells. 
The IP differs from its common counterpart. In the context of immune response, the IP is 
induced by the stimulation of cytokines such as IFN-γ and TNF-α, and then the β1, β2 
and β5 components of the constitutive proteasome are replaced by low molecular mass 
protein 2 (β1i/LMP2), multicatalytic endopeptidase complex-like-1 (β2i/MECL-1), and 
β5i/LMP7. In addition, the IP also has an 11S regulatory structure or PA28 instead of the 
19S RP of the 26S proteasome. Such replacement allows the IP to generate improved 
antigenic peptides for major histocompatibility complex (MHC) class I-mediated immune 
responses (137, 138). 
 
Fig 3.9: The structure of the constitutive proteasome and immunproteasome. Tumor necrosis factor 
(TNF-) and interferon (IFNγ) induce formation of immunoproteasome subunits LMP7, LMP2 and 
MECL-1 subunits which replace the constitutive catalytic subunits β5, β1 and β2, respectively. Taken 
from (139). 
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3.1.6.2. Function of constitutive proteasome and Immunoproteasome  
3.1.6.2.1. Proteasome function in MHC class I antigen processing 
The ubiquitin–proteasome system is central in protein quality control and degradation in 
the mammal cells, which allow them to be involved in many of cellular processes 
including the cell signaling transduction, cell division, cell death, differentiation and 
migration(140, 141). However, the functions of proteasome in immune cell are still 
largely unclear. It has been well described that the proteasome plays a crucial role in 
MHC I antigen processing. Antigen recognition by cytotoxic T lymphocytes (CTLs) 
occurs through the interaction of their T cells receptors (TCRs) with peptide–MHC class I 
complexes. Both, intercellular and extracellular proteins are sources of antigenic 
peptides which are generated though the proteasome degradation (142). The 
proteasome is the protease that determines the carboxy-terminal anchor residues of 
MHC class I binding peptides and produces peptides of 8–9 amino acids that can bind 
directly to the peptide binding cleft of MHC class I molecules. In addition, amino 
terminally extended precursor peptides are also produced by proteasome, and are then 
processed further by aminopeptidases in the cytoplasm (143). It is generally assumed 
that the immunoproteasome improves quality and quantity of generated class-I ligands 
(144). It has been demonstrated that immunoproteasomes intensively increase the 
abundance and diversity of class-I ligands (145). Due to the recent study of the crystal 
structures of the constitutive proteasome and immunoproteasome, it was able to provide 
us an explanation for enhanced antigen processing by immunoproteasomes. It has been 
found that the β1i substrate binding channel is lined with hydrophobic amino acids, 
which finally leads to the enhancement of degradation of peptides into small nonpolar 
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residues (146). The β5i have the peptide bond hydrolysis ability which is favored by an 
increased hydrophilicity of the active site and additional hydrogen bonds shaping the 
oxyanion hole (146).  
3.1.6.2.2. Modulation of immune signaling pathways 
In recent years, it became apparent that both constitutive proteasome and 
immunoproteasomes not only function to process MHC-I ligands, but also possess 
additional immunological functions. It has been reported that LMP2/β1i-deficient bone 
marrow-derived dendritic cells infected with an influenza virus produced less IFN-α, IL-
1β, IL-6 and TNF-α as compared to wild-type counterparts, indicating the crucial role of 
immunoproteasome in innate immune responses. The reduced ability to produce 
cytokines in LMP2/β1i-deficient cells has been associated with compromised NF-kB 
signaling (147). It has been shown that the constitutive ubiquitin-proteasome system is 
involved in NF-κB pathway activation through at least three steps: degradation of the 
NF-κB inhibitor IκB, processing of NF-κB precursors and activation of the IκB kinase 
(IKK) through a degradation-independent mechanism (148). However, contradictory 
findings have been reported on the role of the immunoproteasome for the degradation of 
IκBα and the activation of the canonical NF-κB pathway. Evidence in both knockout mice 
samples and humans with immunoproteasome mutations implicate a contradictory role 
of the immunoproteasome in modulating NF-κB signaling. One study reported that, 
immunoproteasome-deficient mice showed a defect in proteolytic processing of NF-κB 
precursors (p100/p105) and decreased degradation of IκBα (149, 150). Contrary to this 
research, another group using chemical genetic approaches showed that the catalytic 
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activity of the immunoproteasome subunits β1i and β5i is not required for canonical NF-
kB activation (151). This difference may be due to the different cell line models, which 
were used in their laboratories. Therefore, more solid studies need to be performed to 
find out how immunoproteasomes may modulate the NF-κB pathway.  
3.1.6.2.3. The role of immunoproteasomes in immune cell 
T cell differentiation 
CD4 T cells play the critical roles in regulating adaptive immunity to a variety of 
infectious diseases. They are also involved in autoimmunity and chronic inflammatory 
diseases including arthritis, inflammatory bowel disease (IBD), asthma, and IPF. Naive 
CD4+T cells can differentiate into different cells lineages such as Th1, Th2, and Th17 
and regulatory T cells depending on the cytokines in the microenvironment (152). 
Several studies have demonstrated that immunoproteasomes shape the T cell repertoire 
and are responsible for the survival and expansion of T cells after virus infection (153, 
154). Apart from that, it has been reported that immunoproteasome subunit LMP7 
deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell 
differentiation. This study may be able to explain the therapeutic effect of LMP7 inhibitor 
ONX 0914 in experimental diabetes, arthritis, and colitis mice models (155). 
Regulation of macrophage activation 
It has been previously demonstrated that the proteasome serves as a central regulator 
of inflammation and monocyte and macrophage function (156). One of the monocyte 
and macrophage functions is the response to inflammatory stimuli such as LPS and 
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releases a large amount of the proinflammatory cytokines TNF-, IL-1β and IL-6. It has 
been demonstrated that inhibition of proteasome activity by the proteasome inhibitor 
MG132 modulates proinflammatory cytokines production and expression of their 
receptors in the macrophage cell line U937 cells which involved the inhibition of NF-κB 
and AP-1 activation (157). It has also been that reported pretreatment of RAW 264.7 
macrophage-like cells with the proteasome inhibitor lactacystin resulted in a dose 
dependent inhibition of LPS-induced TNF-α. Further studies proved that lactacystin 
blocked the LPS-induced ERK phosphorylation but failed to inhibit IRAK-1 kinase activity 
(158). However, so far, there are only few studies about the role of immunoprotesome in 
macrophage function. One study by Julia Reis suggested that constitutive proteasome 
subunits are replaced by immunoproteasome subunits after LPS treatment of RAW264.7 
cells. Macrophages derived from mice with LMPs knockout exhibited dysregulated 
cytokine production in response to LPS in vitro (159). Specifically, NO production and IL-
1β and IL-6 secretion from LMP deficient macrophages were markedly reduced 
compared to the Wt counterpart, whereas TNFα levels were unexpectedly unchanged in 
LMP-/- macrophages. Further studies indicated that the LPS-induced MyD88 pathway 
was normal, while the TRIF/TRAM and IRF-3 pathways were defective in LMP-/- 
macrophages (160). These studies reveal a novel active function of the 
immunoproteasome subunits, which suggest the complexes of immunoproteasome in 
the regulation of immune cells.  
Though some studies were carried out to evaluate the function of proteasome in macro-
phages, the role of proteasome, particularly of the immunoprotesome, in alveolar macro-
phage biology is largely unknown.
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3.2. Project aims 
Accumulating evidence indicates a crucial role of immunoprotesome for macrophage 
activation. In view of the contribution of impaired polarization of alveolar macrophages in 
acute and chronic lung diseases, the aim of this study was to characterize the function of 
the immunoprotesome on the regulation of alveolar macrophage polarization. 
The following objectives were pursued: 
 Using different sources of alveolar macrophages, primary and cell lines to establish 
an LPS/IFNγ or IL-4 induced M1 or M2 polarization model in vitro. 
 Investigating whether the proteasome and immunoproteasome subunit expressions 
were induced at both protein and mRNA levels during M1 or M2 polarization. 
 Monitoring the kinetics of the expression and activity of the immunoproteasome 
expression and activity during macrophage polarization. 
 Determining whether the immunoproteasome subunits LMP2 and -7 are functionally 
relevant for macrophage polarization. 
 Identifying polarization associated changes of intracellular signaling related to the 
LMP2 and -7 deficiencies using appropriate knock out mice. 
 Investigating whether an immunoproteasome subunit LMP7 specific inhibitor has a 
similar effect as a LMP7 knock out. 
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3.3. Chapter 1 - Results 
3.3.1. Characterization of the polarization pattern of different alveolar macrophage 
types 
A wide variety of sources of macrophages has been used for macrophage polarization 
studies (161). Although there are several reports about the polarization of alveolar 
macrophages under different diseases conditions, here we are describing the 
polarization of alveolar macrophages into respective M1 and M2 phenotypes at the in 
vitro level for the first time. To gain insight whether the polarization depends on the 
alveolar macrophage (AMs) background, we first characterized the plasticity of primary 
AMs isolated from BALB/c and C57BL/6 mice, as well as the SV40 immortalized 
BALB/c-derived AM cell line MH-S. To trigger polarization, cells were treated either with 
LPS and IFNγ to induce M1-like phenotypes or with IL-4 for induction of M2 polarization.  
To determine if polarized alveolar macrophages show different cell morphology, bright 
field microscopy was used to examine the cell morphology after 24 h of polarization. Cell 
morphology of AMs was clearly altered depending on the stimulus as exemplarily shown 
for C57BL/6 AMs (Figure 3.10): In comparison to untreated and non-polarized cells 
(M0), the shape of M1-polarized macrophages was globular, while M2-polarized 
macrophages exhibited a flattened and adherent morphology. 
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Figure 3.10 Representative morphology of 24 h polarized M1 and M2 alveolar macrophage. Primary 
alveolar macrophages from C57BL/6 mice were polarized into M1 or M2 for 24 h by stimulation with 
LPS/IFNγ or IL-4, respectively. Non-polarized cells (M0) served as controls. Cell morphology was 
examined by bright field microscopy with 20-fold magnification. Results are representative for at three 
independent experiments. 
To better understand the global gene expression patterns in polarized AMs, we used 
Illumina microarrays to identify up-regulated genes in M1 and M2 cells. We found that 
162 genes were induced in M1 condition (see heat map in Figure 3.11). 
3. Chapter1 - Results 
- 40 - 
 
 
Figure 3.11 Heat map analysis of global gene expression in M1 polarized alveolar macrophages. 
Visualization of gene expression changes in 24 h polarized primary AMs from C57BL/6 mice as a heat 
map. Up-regulated genes in M1 are shown in red. The genes with P<0.05 were displayed. Results are from 
three individual C57BL/6 wt mice.  
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As we expected, a number of M1 markers as described in the literature were 
upregulated in our microarray analysis, among them Tnf, Il1b, and Il12b. However, 
Nos2, as one of most frequently used M1 marker, was not shown to be induced in M1 
cells, which might be due to a technical reason. We also selected these markers to 
characterize the polarization profile of the different AMs. Comprehensive gene 
expression analysis by qPCR for activation of specific genes confirmed markedly 
increased expression of these M1 marker genes in M1 polarized cells compared to 
untreated (M0) and M2 polarized cells (Fig. 3.12).  
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Figure 3.12 Alveolar macrophages show characteristics of M1 polarization by marker 
genes profiling. M1 marker gene expression analysis of MH-S cells or primary alveolar macrophages 
from BALB/c or C57BL/6 mice polarized for 24 h: Nos2, Tnf, Il1b, Il12b, relative to Actb (β-actin) 
expression. Results are representative for three independent experiments, bd, below detection. 
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To investigate the genes associated with M2 AMs polarization, microarray analysis 
identified 35 genes to be induced at M2 condition, which are displayed in the heat map 
below (Figure 3.13). Among these genes, Arg1, Retnla and Ccl17 have been well 
described as M2 markers genes. They were selected for the characterization of M2 
polarization of AMs from different sources. 
 
Figure 3.13 Heat map analysis of global genes expression in M2 polarized alveolar macrophages. 
Visualization of gene expression for 24 h polarized primary AMs from C57BL/6 mice as a heat map. Up-
regulated genes in M2 are shown as pink. The genes with P<0.05 were displayed. Results are from three 
individual C57BL/6 wt mice. 
IL-4 treatment induced uniform expression of M2 marker genes in primary AMs while 
marker gene expression was less consistent in IL-4 treated MH-S cells: Expression of 
Arg1 and Mrc1were stimulated in a M2 specific manner in all three types of AM, while 
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Ccl17 and Retnla (Fizz-1) were only found elevated in primary AMs, but not in MH-S 
cells (Fig. 3.14). 
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Figure 3.14 Alveolar macrophages show characteristics of M2 polarization by maker 
genes profiling. M2 marker gene expression analysis of MH-S cells or primary alveolar macrophages 
from BALB/c or C57BL/6 mice polarized for 24 h: Arg1 (Arginase1), Ccl17, Retnla (Fizz-1), Mrc1 
(mannose receptor 1), relative to Actb expression. Results are representative for at three independent 
experiments bd, below detection. 
To further confirm the alveolar macrophage polarization at the protein level, we selected 
the most well-known marker gene iNOS for M1 and Arginase1 for M2 to perform western 
blot analysis. Polarization of alveolar macrophages was confirmed at the protein level for 
primary AMs after 24 h of cytokine stimulation with elevated iNOS (NOS2) expressions 
in M1 and Arg1 in M2 polarized cells, respectively (Fig. 3.15). 
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Figure 3.15 M1 (iNOS) and M2 (Arginase1) protein analysis shows characteristic M1/M2 alveolar 
macrophage polarization. M1 (iNOS) and M2 (Arginase1) markers were evaluated on protein level in 
primary alveolar macrophages from C57BL/6 mice polarized for 24 h. Results are representative for three 
independent experiments. 
3.3.2. Proteasome and Immunoproteasome expression and activity during alveolar 
macrophage polarization. 
To investigate regulation of proteasome related genes in polarized AMs, we screened 
the expression pattern of 60 genes as shown in the heat map (Figure 3.16). We found 
that a number of constitutive proteasome and immunoproteasome subunits were 
induced in M1 polarized macrophages but generally not in M2-polaized AMs. 
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Figure 3.16 Heat map analysis of proteasome related genes expression in polarized alveolar 
macrophages. Visualization of gene expression for 24 h polarized primary AMs from C57BL/6 mice as a 
heat map. Up-regulated genes in M1 and M2 are shown as red. The genes with P<0.05 were displayed. 
Results are from three individual C57BL/6 wt mice.  
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To validate the regulation of the expression of constitutive proteasome subunits and 
proteasome regulators during AM polarization, gene expression of the PSMA3, 
PSMD11, PSME1/2/3 and PSMB5/6/7 subunits was profiled by qPCR. Interestingly, the 
mRNA levels of all the proteasome subunits were uniformly induced after 24 h at M1 Fig. 
3.17). 
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Figure 3.17: mRNA expression of proteasome subunits is induced in both M1 and M2 polarized 
alveolar macrophages. Proteasome subunit gene expression in MH-S cells or primary alveolar 
macrophages from BALB/c or C57BL/6 mice polarized for 24 h: PSMA3, PSMD11, PSME1/2/3 and 
PSMB5/6/7 expression displayed relative to Actb. Results are representative for three independent 
experiments. Note, that we used a linear scale to depict the minor changes in gene expression levels. 
It has been well described that IFNγ can induce expression of immunoproteasome 
subunits in a variety of cell types through the STAT1 pathway (162), which causes the 
replacement of constitutive proteasome by immunoproteasomes. As we used IFNγ plus 
LPS to induce the M1 macrophage phenotype, we firstly speculated that the expression 
of the immunoproteasome subunits LMP2, MECL-1, and LMP7 is induced in M1 
macrophages. According to our expectation, our microarray data revealed that 
immunoproteasome subunits LMP2, MECL-1, and LMP7 were induced in M1 AMs. The 
gene expression of these immunoproteasome subunits was further analyzed by qPCR in 
both M1 and M2. While mRNA levels of all three immunoproteasome subunits (Psmb8, 
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9, 10 for LMP7, LMP2, and MECL-1, respectively) were uniformly induced after 24 h, 
under conditions of M1 polarization, no reproducible changes were observed for M2 
polarization conditions (Fig. 3.18). 
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Figure 3.18: mRNA expression of immunoproteasome subunits LMP2 and LMP7 is induced in M1 
but not in M2 polarized alveolar macrophages. Immunoproteasome subunit gene expression in MH-S 
cells or primary AMs from BALB/c or C57BL/6 mice polarized for 24 h: Psmb9 (LMP2), Psmb10 
(MECL-1), and Psmb8 (LMP7) expression displayed relative to Actb. Results are representative for three 
independent experiments. 
Western blot analysis for the standard 20S proteasome α1-7 and the two 
immunoproteasome subunits LMP2 and LMP7 revealed moderate basal expression of 
immunoproteasome subunits which was strongly upregulated in M1-polarized AMs 
compared to unstimulated controls. Remarkably, however, protein expression of both, 
LMP2 and in particular LMP7, were elevated in M2 cells (Fig. 3.19) indicating 
posttranscriptional regulation of immunoproteasome expression upon M2 polarization of 
AMs. The protein level of α1-7 was also induced in both M1 and M2 cells.  
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Figure 3.19: Protein expression of constitutive proteasome and immunoproteasome subunits LMP2 
and LMP7 were induced in both M1 and M2 polarized alveolar macrophages. Immunoproteasome 
subunit LMP2 and LMP7 protein expression in primary alveolar macrophages from C57BL/6 mice 
polarized for 24 h. Densitometric analysis was done from three independent experiments. 
Specific activities of the immunoproteasome subunits can be analyzed using specific 
activity based probes which have been developed recently (163, 164). To further 
corroborate the existence of catalytically active immunoproteasomes in polarized AMs 
we assessed the activity of immunoproteasome and standard proteasome subunits 
using a set of fluorescently labeled activity-based probes (ABPs) with distinct binding 
specificities to the different active sites after 24 h of cytokine stimulation (Fig. 3.20). 
These ABPs covalently bind to the active-site threonine of the catalytic subunits and can 
be used to label active proteasome complexes in native lysates. Labeled lysates are 
then separated by SDS-PAGE to attribute activities to single subunits. . Both, immuno- 
and constitutive proteasome (β1, β2 and β5) activities were significantly elevated in M1 
polarized alveolar macrophages compared to the control M0 state but only β1 was 
considerably elevated also in M2-polarized AMs.  
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Figure 3.20: Activity of constitutive proteasome and immunoproteasome subunits LMP2 and LMP7 
were induced in both M1 and M2 polarized alveolar macrophages.  Proteasome activity, in polarized 
alveolar macrophages from C57BL/6 mice detected after 48 h stimulation by activity-based probes (ABP) 
MV151 (labeling all catalytically active β-subunits), LW124 (β1 and LMP2) or MVB127 (β5 and LMP7). 
Densitometric analysis displays the combined data from three experiments. Picture provided courtesy of 
Oliver Vosyka. 
3.3.3. Time course of immunoproteasome subunit expression during alveolar 
macrophage polarization. 
The majority of studies focused on only one single time point of macrophage 
polarization, which cannot provide full information about the dynamic changes of genes 
during the whole range of polarization. To study the kinetics of the increased expression 
of LMP2, MECL-1, and LMP7 during IFNγ-driven AM polarization, primary macrophages 
were treated with LPS or IFNγ or IL-4 for 6, 24, 48, and 72 h, respectively. Firstly, we 
investigated the expression of respective M1 marker Tnf or M2 maker Ccl17. At M1 
polarizing conditions, gene expression analysis revealed maximal levels of the M1 
marker Tnf after 6 h of LPS or IFNγ treatment which returned to baseline after 72 h (Fig. 
3.21). At the same time, expression levels of LMP2, MECL-1, and LMP7 were increased 
after 6 h and remained elevated for 72 h. In M2 polarized AMs, expression of the M2 
marker Ccl17 increased dramatically up to 72 h. For immunoproteasome subunits, 
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however, we only observed a moderate increase of MECL-1 but no change in gene 
expression levels of LMP2 and LMP7. 
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Figure 3.21: Gene expression analysis of immunoproteasome subunits during primary alveolar 
macrophage polarization. Alveolar macrophages from C57BL/6 mice were treated with IFNγ or IL-4 for 
6, 24, 48 and 72 h and mRNA was analyzed to detect expression of Tnf, Ccl17, Psmb8 (encoding LMP7), 
Psmb9 (LMP2) and Psmb10 (MECL-1). Results are displayed as fold change over control relative to Actb 
expression and are representative for three independent experiments. 
Following the mRNA profile, we investigated protein expression of constitutive 
proteasomes and immunoproteasomes in primary macrophages and MH-S. Cells were 
treated with LPS or IFNγ and IL-4 or IL-13 for 6, 24, 48, and 72 h, respectively. In 
contrast to the mRNA results, protein levels of constitutive proteasome and 
immunoproteasome subunits increased further from 24 to 72 h in  both M1 and M2 
polarizing conditions in primary AMs (Fig. 3.22 A) and in the MH-S cell line (Fig. 3.22 B).  
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Figure 3.22: (A, B) Proteins level analysis of constitutive proteasome and immunoproteasome 
subunits during primary alveolar macrophage polarization. Alveolar macrophages from C57BL/6 
mice and MH-S cell line were treated with M1 condition LPS or IFNγ and IL-4 or IL-13 for 6, 24, 48, and 
72 h, respectively, which were analyzed to detect protein expression of constitutive proteasome a1-7 and 
immunoproteasome subunits LMP2 and LMP7 during polarization of primary alveolar macrophages from 
C57BL/6 mice. Results are representative for two independent experiments; the control (c) is the 
unstimulated 24 h control. 
In accordance with our expression data, immuno- and standard proteasome activities 
increased as well after 48 and 72 h in both M1 and M2 polarized AMs (Fig.3.23). These 
results clearly show IL-4-induced formation of active immunoproteasomes during M2 
polarization of alveolar macrophages. In contrast to IFNγ-mediated transcriptional 
induction of immunoproteasomes, this may involve the posttranscriptional mechanisms 
of protein stabilization. Our kinetic data also indicate that elevated immunoproteasome 
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expression and activity are not the driving force for M1 and M2 marker gene expression 
but rather a consequence of the distinct polarization states.  
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Figure 3.23: Proteasome activity analysis during primary alveolar macrophage polarization. 
Proteasome activity in polarized alveolar macrophages from C57BL/6 mice detected by ABPs MV151 
(labeling all catalytically active β-subunits), LW124 (β1 and LMP2) or MVB127 (β5 and LMP7). Data are 
representative for three independent experiments; the control (c) is the unstimulated 24 h control. Picture 
provided courtesy of Oliver Vosyka. 
3.3.4. Deficiency of LMP2 and LMP7 immunoproteasome subunits does not affect 
M1 but enhance M2 alveolar macrophage polarization  
To investigate, whether immunoproteasome activity and expression in AMs is of any 
functional relevance for macrophage polarization, we polarized primary AMs from LMP2-
/- and LMP7-/- mice towards M1 or M2 phenotypes, respectively. As a first step, we 
performed the Water soluble Tetrazolium (WST) salt cell viability assay to exclude any 
unspecific effect after LMPs knock out and polarization. After 24 h of M1 and M2 
polarization, both the AMs from wt and LMPs-/- showed no treatment or genotype 
depending effect on cell viability (Fig. 3.24).   
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Figure 3.24: WST cell viability assay. WST assay of primary alveolar macrophages from C57BL/6 Wt, 
LMP2
-/-
 or LMP7
-/- 
mice polarized towards M1 phenotype (LPS and IFNγ for 24 h). Unpolarized cells 
(M0) were set to 100 %. Data are combined from measurements of 3 individual mice. 
At M1 polarizing conditions, mRNA expression of M1 markers (Nos2, Tnf, Il1b and Il12b) 
was clearly increased in AMs of wt and LMP2-/-, and LMP7-/- mice (Fig. 3.25). 
Nevertheless, there was no M1 consistent alteration in marker expression, although the 
extent of mRNA induction was different between genotypes: e.g. LMP7-/- AMs exhibited 
a reduced induction of Nos2 and Tnf; LMP2-/- AMs had increased levels of Nos2 and 
Il12b but a decreased level of Tnf compared to wt mice, while there was no difference in 
Il1b expression. 
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Figure 3.25: Deficiency of LMP2 and LMP7 immunoproteasome subunits does not affect M1 
alveolar macrophage polarization (A, B) M1 marker gene expression analysis of primary alveolar 
macrophages from C57BL/6 wt, LMP2-/- or LMP7-/- mice polarized towards M1 phenotype (LPS and 
IFNγ for 24 h): expression of Nos2 (iNos), Tnf, Il1b, Il12b is shown relative to Actb. Results are 
representative for three independent experiments. 
Interestingly, our heat map array analysis revealed that 21 and 43 M2 signature genes 
expression were significantly enhanced in LMP2-/- and in LMP7-/- M2 cell respectively, 
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compared to wt cells (Fig. 3.26). Among these genes, the major M2 marker Arg1, and 
Retnla as well as the Th2 cytokine Ccl17 were increased in immunoproteasome 
deficient alveolar macrophages. 
A B
 
Figure 3.26: Heat map analysis of M2 related genes expression altered in immunoproteasome 
deficient alveolar macrophages. (A) The left map includes 21 genes which expression levels were 
significantly enhanced in LMP2-/- M2 cell, compared to wt counterpart. (B) The right map includes 43 
genes whose expression levels were significantly enhanced in LMP7-/- M2 cell, compared to wt controls. 
Pink in the heat maps indicates up-regulation. The genes with P<0.05 were displayed. Results were 
normalized to wt-M0, and were from three individual C57BL/6 wt or LMP2-/- or LMP7-/- mice.  
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Further qPCR experiments confirmed the results from our microarray analysis, as gene 
expression of the major M2 markers Arg1, Retnla and Ccl17 was slightly increased in 
LMP2-/- and clearly upregulated in LMP7-/-AMs, compared to wt cells (Fig. 3.27). 
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Figure 3.27: Deficiency of LMP2 and LMP7 immunoproteasome subunits affects M2 alveolar 
macrophage polarization. (A, B) M2 marker gene expression analysis of primary alveolar macrophages 
from C57BL/6 wt, LMP2-/- or LMP7-/- mice polarized towards M2 phenotype (IL-4 for 24 h): expression 
of Arg1 (Arginase1), Ccl17, Retnla (Fizz-1), Mrc1 (mannose receptor 1) relative to Actb expression. 
Results are representative for three independent experiments. 
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Because CCL17 is thought to play a crucial role as an M2 effector cytokine for Th2-
related lung diseases, we validated the Ccl17 expression data by analyzing CCL17 
protein release in supernatants from polarized AMs using a specific ELISA. As shown in 
Figure (Fig. 3.28), CCL17 release was induced in IL-4 treated M2 polarized wt cells. It is 
important to note that secretion of CCL17 was significantly enhanced in M2 polarized 
AMs from LMP2-/- and LMP7-/- mice compared to wt cells. Taken in combination, our 
results clearly indicate that expression and activity of distinct immunoproteasome 
subunits is of functional relevance for the plasticity of alveolar macrophages with 
subsequent release of effector cytokines. 
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Figure 3.28: Deficiency of LMP2 and LMP7 immunoproteasome subunits enhances the release of 
Th2 chemokine CCL17 from M2 alveolar macrophage polarization. CCL17 secretion measured in 
supernatants of polarized primary alveolar macrophages from C57BL/6 wt, LMP2-/- or LMP7-/- mice 
(M1: LPS and IFNγ; M2 IL-4 for 24 h). Results show the mean ± SEM for 4 replicates and are 
representative for 2 independent experiments. bd, below detection. 
It has been well described that the effects of IL-13 on immune cells are similar to those 
of the closely related cytokine IL-4 due to their sequence similarity and similar structure 
(165). In addition, both of them can induce the phosphorylation of STAT6 as they share 
3. Chapter1 - Results 
- 58 - 
 
a common receptor IL-4Ra (166). Therefore, it seems reasonable to investigate the role 
of immunoproteasome in IL-13 induced M2 alveolar macrophage polarization, as shown 
in Figure (Fig. 3.29) 
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Figure 3.29: Deficiency of the LMP7 immunoproteasome subunit enhances IL-13 induced M2 
alveolar macrophage polarization. M2 marker gene expression analysis of primary alveolar 
macrophages from C57BL/6 wt, LMP2-/- or LMP7-/- mice polarized towards M2 phenotype (IL-13 for 24 
h): expression of Arg1 (Arginase1), Ccl17, Retnla (Fizz-1), Mrc1 (mannose receptor 1) relative to Actb 
expression. Results are from three individual C57BL/6 wt or LMP7-/- mice. 
3.3.5. No alteration of M1 transcription factors in LMPs deficient macrophages 
To study the molecular mechanism of dysregulated AM polarization, we further analyzed 
transcription factors that are involved in the transcriptional activation of M1 or M2 
macrophage polarization, such as NF-κB subunits NF-κB 1 (p105/p50) and Rela (p65), 
3. Chapter1 - Results 
- 59 - 
 
as well as Irf-4 and -5 (60). We found no genotype-dependent changes for RNA 
expression of the NF-κB genes Rela and NF-κB 1, or Irf-5 in wt, LMP2-/- or LMP7-/- AMs 
(Fig.3.30).  
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Figure 3.30: Deficiency of LMP2 and LMP7 has no impact on NF-κB 1, Rela and Irf-5 expression in 
M2 alveolar macrophages. NF-κB 1, Rela and Irf-5 gene expression relative to Actb in primary alveolar 
macrophages from C57BL/6 wt, LMP2
-/-
 or LMP7
-/-
 mice, polarized towards M1 (LPS and IFNγ) or M2 
(IL-4) phenotype for 24 h. Results are from three independent experiments. 
Irf-4 has been described as a key regulator of M2 macrophage polarization in bone 
marrow-derived macrophages (53), but not yet for alveolar macrophages. We thus 
confirmed its M2-specific mRNA induction in different primary AMs from C57BL/6 or 
BALB/c mice and in the MH-S cell line (Fig. 3.31 A). On the protein level IRF-4 
transiently increased with highest levels after 48 and 72 h of IL-4 stimulation in primary 
C57BL/6 AMs (Fig. 3.31 B) and MH-S cells. 
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Figure 3.31 Irf-4 expression in primary alveolar macrophages is induced in M2 polarized alveolar 
macrophages (A) Irf4 gene expression relative to Actb in MH-S cells or primary alveolar macrophages 
from BALB/c or C57BL/6 mice polarized for 24 h. (B) Time course of IRF-4 protein expression in 
primary alveolar macrophages from C57BL/6 mice treated with LPS, IFNγ or IL-4 for up to 72 h. Results 
are from two independent experiments. 
We next determined whether IRF-4 protein was induced by IL-13 which also induces M2 
alveolar macrophage polarization.  We found that IL-13 showed a similar pattern in 
induction of IRF-4 during polarization: IRF-4 also transiently increased to highest levels 
after 48 and 72 h of IL-13 stimulation in primary C57BL/6 AMs (Fig. 3.32). In addition, 
we observed that phosphorylation of STAT6 was induced during polarization.  
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Figure 3.32 Irf-4 expression in primary alveolar macrophages is induced in IL-13 polarized alveolar 
macrophages. Time course of LMP2, LMP/, and IRF-4 protein expression and phosphorylation of 
STAT6 in primary alveolar macrophages from C57BL/6 mice treated with IL-13 for up to 72 h. Results 
are from two independent experiments. 
As shown in above data, the kinetics of IRF-4 upregulation was similar in both IL-4 and 
IL-13 treatment. Therefore, we further investigated the kinetics of Irf4 expression in 
LMP7 deficient AMs. As shown in (Fig. 3.33), Irf4 was rapidly induced within 6 h and 
stayed elevated till day 3 after IL-4 treatment in wt AMs, but was markedly amplified in 
LMP7 deficient AMs. 
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Figure 3.33: Deficiency of the LMP7 immunoproteasome subunit enhances Irf4 expression during 
M2 alveolar macrophages polarization. Irf4 gene expression in primary alveolar macrophages from 
C57BL/6 wt, LMP2-/- or LMP7-/- mice treated with IL-4 for up to 72 h to polarize them towards the M2 
phenotype. Results are combined data from three experiments. 
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As shown above, Irf4 gene expression was enhanced in LMP7-/- AMs, thus it is 
necessary to confirm this finding on the protein level. As shown in Figure 3.34, IRF-4 
protein was also induced within 3 h in wt AMs after IL-4 treatment. n Both, LMP2-/- and 
LMP7-/- AMs, showed comparatively higher IRF-4 levels, in particular at later time points 
after IL-4 treatment. 
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Figure 3.34: Deficiency of LMP2 or LMP7 immunoproteasome subunits enhances IRF-4 protein 
expression during M2 alveolar macrophages polarization. Time course of IRF-4 protein expression 
within 180 min after IL-4 treatment in primary alveolar macrophages from C57BL/6 wt, LMP2-/-, or 
LMP7-/- mice. Results are representative for two independent experiments. 
3.3.6. Deficiency of LMP2 and LMP7 immunoproteasome subunits alters signaling 
towards alveolar macrophage M2 polarization 
Elevated IRF-4 levels in LMP2 and LMP7 -/- AMS are indicative of altered M2 
polarization upon immunoproteasome deficiency. We thus investigated whether LMP2-/- 
and LMP7-/- alveolar macrophages have altered signaling properties in response to IL-4 
treatment by assaying the phosphorylation status of STAT6. Independent of the 
macrophage genotype, we observed distinct activation of STAT6 in M2-polarized AMs. 
To gain insight into early IL-4 signaling, a more immediate time window of 0 - 180 min 
was chosen to monitor STAT6 and also AKT activation. While STAT6 was steadily 
phosphorylated in wt cells from 15 min to 180 min peaking at 60 minutes after IL-4 
stimulation (Fig. 3.35), STAT6 phosphorylation occurred with a similar time kinetic but at 
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higher levels in LMP2-/- alveolar macrophages (Fig. 3.35). AKT phosphorylation was 
steadily increased in wt cells from 15 min to 180 min but with no obvious change in 
LMP2-/- cells (Fig. 3.35). In contrast, activation of both STAT6 and AKT was enhanced 
in LMP7-/- AMs compared to wild type cells, particularly at later time points (Fig. 3.35). 
This signaling data further corroborates that LMP2-/- and LMP7-/- AMs have intrinsic 
similarity that govern a signaling response to IL-4-mediated signaling towards M2 
macrophage polarization. 
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Figure 3.35: Deficiency of LMP2 and LMP7 affects M2 signaling. Time course of STAT6 (pTyr
641
) 
and AKT (pSer
473
) pathway activation within 180 min after IL-4 treatment in primary alveolar 
macrophages from C57BL/6 wt, LMP2
-/-
 or LMP7
-/-
 mice. Results are representative for two independent 
experiments. 
3.3.7. LMP2 and LMP7 immunoproteasome deficiency affects IL-4Ra protein 
expression. 
Since the phosphorylation status of STAT6 and AKT was altered in LMP2 and LMP7 
deficient AMs, this indicated an alteration upstream of these IL-4 signaling mediators. As 
it is well known that the immunoproteasome presents as important machinery regulating 
the protein turnover in the cells, we decided to test the possibility that the IL-4Ra might 
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be degraded by immunoproteasome subunits. To test whether IL4Ra is differentially 
expressed in wt and immunoproteasome deficient AMs, western blotting was performed 
to detect the IL-4Ra protein level in wt, LMP2-/- or LMP7-/- AMs. As shown in Figure 
(Fig. 3.36), the overall IL-4Ra protein level was present at a higher level in LMP2-/- and 
LMP7-/- AMs compared with wt cells. 
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Figure 3.36 Deficiency of LMP2 and LMP7 immunoproteasome increases IL-4Ra protein 
expression. IL-4Ra protein expressions within 0-180 min after IL-4 treatment in primary alveolar 
macrophages from C57BL/6 wt, LMP2-/- or LMP7-/- mice were detected by western blotting. Results are 
representative for two independent experiments.  
To determine if the increased IL-4Ra protein expression in LMP2-/- or LMP7-/- cells is 
dependent on mRNA level changes, we further investigated the IL-4Ra mRNA 
expression in polarized AMs from wt, LMP2-/- or LMP7-/- mice. As shown in (Figure 3.37), 
there are no significant differences for the IL-4Ra mRNA expression in the AMs from wt, 
LMP2-/- or LMP7-/- mice, which indicate that the accumulative IL-4Ra protein in LMP2-/- or 
LMP7-/- AMs is due to post-transcriptional effects such as deficient protein degradation 
due to immunoproteasome deficiency. 
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Fig. 3.37: No change in Il4ra expression level between polarized alveolar macrophages from wt, 
LMP2-/- and LMP7-/- mice. Il4ra expression analysis of primary alveolar macrophages from C57BL/6 
wt, LMP2-/- and LMP7-/- mice polarized for 24 h with IL-4, relative to Actb expression. Results are 
combined data from three experiments. 
3.3.8. The Iimunoproteasome subunit LMP7 specific inhibitor ONX 0914 enhances 
M2 alveolar macrophage polarization 
Since we have demonstrated the critical role of immunoproteasome in M2 AMs 
polarization by using LMP2 and LMP7 knock out mice, it will be particularly meaningful 
to test whether a similar effect will be achieved by using an immunoproteasome specific 
inhibitor. Onyx pharmaceuticals developed ONX 0914 to be an inhibitor of the 
immunoproteasome subunit LMP7, with minimal cross-reactivity for the constitutive 
proteasome. One recent study has reported that the LMP7-specific inhibitor ONX 0914 
is able to prevent collagen antibody–induced arthritis progression (167). Another newly 
published study has proven that inhibition of the LMP7 subunit prevented lupus disease 
progression by targeting two critical pathways of its disease pathogenesis, i.e. initiation 
of type I IFN activation and autoantibody production by plasma cells (168). We thus 
investigated the possibility of altering the M2 macrophage polarization via inhibition of 
immunoproteasome subunit LMP7 with the specific inhibitor ONX 0914. 
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Firstly, in order to exclude any unspecific toxic side effects of ONX 0914 on M2 
polarization, WST cell viability assay were performed to identify the appropriate dose 
and time point of giving ONX 0914 to AMs. As shown in (Figure 3.38), we investigated 
cell viability at 6 and 24 h time points with a dosage range from 0.1-50 µM, and found 
that ONX 0914 did not cause the cell death from dose range 0.1 to 1 µM at the 6 h time 
point, whereas more than 25% cells died at a dose range of 5 to 50 µM. However, we 
observed that ONX0914 causes a significant dose dependent cell death at the 24 h 
point starting with a dose of 0.2 µM. 
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Figure 3.38: WST cell viability assay of ONX 0914 on cell line MH-S The alveolar macrophage cell 
line MH-S was treated with ONX 0914 at a dose range from 0.1-50 µM respectively at 6 or 24 h time 
points. The 10% cell proliferation reagent WST-1 was added to the cell to measure the cell viability. 
Results are mean + SEM from 4-7 individual experiments. 
To investigate if the ONX 0914 can enhance the M2 signaling pathway and its upstream 
receptor IL-4Rα protein expressions, MH-S cells were pretreated without or with 0.2 or 1 
µM ONX 0914 for 2-4 h, and IL-4 was added for 0 min to 180 min, ONX 0914 blocked 
the degradation of IL-4Rα from 30 to 180 min, resulting in enhanced phosphorylation of 
STAT6 (Fig. 3.40). 
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Figure 3.40: M2 alveolar macrophage polarization signaling is enhanced by LMP7 inhibition. MH-S 
cells were pretreated with or without 0.2 and 1 µM ONX 0914 for 2-4 h, and then treated together with IL-
4 from 0 min to 180 min. IL-4Rα protein level and time course of STAT6 (pTyr641) and pathway 
activation within 180 min after IL-4 treatment in MH-S cells were analyzed by western blotting. Results 
are representative for three independent experiments. 
To further determine if the LMP7 inhibition alters M2 macrophage polarization Arg1, 
Mrc1 and Irf4 mRNA expressions were analyzed in primary alveolar macrophages and 
MH-S cells that had been pretreated with 0.2 or 1 µM ONX 0914 for 2 h and then treated 
with IL-4 for 6 h. We chose this treatment scheme to prevent cytotoxic side-effects of 
ONX-0914. As shown in (Fig. 3.41), the Arg1 gene expression was significantly 
enhanced by ONX 0914 in MH-S cells at both 0.2 and 1 µM ONX 0914 treatment doses 
compared to untreated cells, whereas it was only significantly enhanced in primary AMs 
at a dose of 1 µM ONX 0914. Expression of Mrc1 and Irf4, were significantly enhanced 
by ONX 0914 at both 0.2 and 1 µM ONX 0914 treatment in both MH-S and primary AMs. 
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Figure 3.41: M2 maker gene expression was enhanced by LMP7 inhibition. M2 marker gene exp-
ression (Arg1, Mrc1 and Irf4) in MH-S cells or primary alveolar macrophages (pAM) from C57BL/6 
mice: Cells were pretreated with DMSO or ONX-0914 (0.2 or 1 µM) for 2 h, afterwards IL-4 was added 
for another 4 h. Untreated cells and cells treated only with IL-4 served as controls. Results are the mean + 
SEM of three individual experiments (MH-S) or 3-6 individual mice (pAM).
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3.4. Discussion 
The conversion of human monocyte-derived macrophages by the Th2 cytokine IL-4 into 
a special activation state of inhibited respiratory burst and increased MHC II expression 
was first recognized by Abramson and Gallin in 1990 (169). Siamon Gordon’s lab 
subsequently proposed the concept of an alternative IL-4/IL-13-activated macrophage 
phenotype (now also known as M2), characterized by the up-regulated macrophage 
mannose receptor (MRC1) expression coupled with enhanced MHC II and reduced pro-
inflammatory cytokine levels (170). Since then, numerous studies have investigated 
polarization of mainly bone marrow- and monocyte-derived macrophages. The finding 
that tissue macrophages are of different origin and self-renew throughout life (23, 171, 
172), however, has stimulated research on the polarization capability of tissue resident 
AMs (17).  
3.4.1. Polarization capability of alveolar macrophages 
Here we profiled global gens expression in polarized M1 and M2 alveolar macrophages 
using Illumina microarray system, and demonstrated that the expression of 162 genes 
were significantly induced in M1 AMs and 35 genes were induced in M2 AMs. Within 
these genes, the expression of well described M1 marker genes (Tnf, Il1b, and Il12b) 
and M2 marker genes (Arg1, Relnla and Ccl17) were also shown to be respectively 
induced in M1 or M2 AMs, which was further validated by qPCR analysis. While, no 
induction of Nos2 in M1 and Mcr1 in M2 AMs was detected in microarray analysis, the 
increased expression of these two important markers were confirmed by qPCR for 
mouse primary AMs of two different mouse strains and the MH-S cell line. Therefore, our 
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results demonstrate that alveolar macrophages can be polarized in vitro to classically, 
pro-inflammatory activated M1, or alternatively activated M2 macrophages. In addition, 
we showed that murine alveolar macrophages (AM) of different sources can be 
polarized in vitro to M1 or M2 macrophages. The M1 polarization profile of AMs from the 
MH-S cell line (BALB/c derived) matched well with that of primary cells derived from 
BALB/c and C57BL/6 mice. Obvious differences, however, were observed for some of 
the investigated M2-like gene expression markers. For example, CCL17 is a small 
cytokine belonging to the CC chemokine family that is also known as thymus and 
activation regulated chemokine (TARC). A number of studies have identified CCL17 as a 
marker for M2 or tolerance macrophages which are related processes orchestrated by a 
p50 nuclear factor κB, which suggest the crucial role of M2 in chemoattractant of Th2 
and promotion of Th2 type of immune responses (173). Our unexpected results showed 
that CCL17 was not induced by IL-4 in the MHS cell line, which indicated some 
difference of macrophage biology between cell line and primary macrophages. Thus 
people should consider this factor when using a cell line alveolar macrophage in their 
study model. 
Polarization of AMs has been described for various chronic inflammatory conditions of 
the lungs, for example during infection (86, 174) and allergic asthma (175), upon 
inhalation of sterile irritants such as toxic chemicals (86), or insoluble particles (176), 
and also in response to tumor growth (177). Pulmonary IFNγ and IL-4 production 
coincided with altered polarization of alveolar macrophages and are associated with 
inflammation, resolution, and tissue remodeling (86). They are thus considered to be 
relevant stimuli for AM polarization ex vivo. Impaired polarization of tissue macrophages 
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may be the cause or consequence for development of chronic diseases (66). Cigarette 
smoke-dependent reprogramming of AMs has been considered to contribute to the 
pathogenesis of COPD, as AM transcriptomes of COPD smokers showed a partially M2-
shifted profile compared to healthy smokers and non-smokers (178). Also, idiopathic 
pulmonary fibrosis (IPF), a fatal fibrotic disease of the lung, has been associated with 
alternative AM activation (179) and M2-related production of CCL17 and CCL22 was 
proposed as a new marker for IPF(180). Hence, several signals characteristically 
expressed by M2 macrophages are known for their pro-fibrotic activity and suggest that 
these cells act as master regulators of fibrosis (120). Accordingly, restoring the M1/M2 
balance by serum amyloid P has been effective in reducing fibrosis and remodeling 
caused by bleomycin application in mice (181). Targeted overexpression of TGF-β1 in 
the lungs of mice which is used as a model system for IPF, also demonstrated the 
significance of the M1/M2 balance with severe pulmonary inflammation followed by 
subsequent accumulation of alternatively activated BAL macrophages, while clodronate 
mediated AM depletion ameliorated the TGF-β1 driven fibrotic phenotype (182). 
Altogether, accumulating evidence suggests that excessive M2 activation of AMs 
contributes to the development of chronic lung disease.  
3.4.2. Expression and activity of immunoproteasomes in polarized alveolar 
macrophages 
It has been well described that IFNγ induces the expression of the immunoproteasome 
subunit in a variety of cell types in a STAT1 dependent manner. As we used LPS plus 
IFNγ to polarize alveolar macrophages into M1 in vitro, we firstly analyzed the 
expression of the immunoproteasome subunits in microarray data, and then investigated 
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the expression of the immunoproteasome subunit in polarized macrophages. Our results 
showed that in murine AMs, formation of active immunoproteasomes is not only induced 
by Th1 related stimuli such as IFNγ/LPS but also by Th2 cytokines, such as IL-4. In M1 
polarization, LMP2 and -7 but also MECL-1 gene expression was concertedly 
upregulated by LPS/IFNγ. Expression of immunoproteasome subunits steadily increased 
during M1 polarization up to 72 h, reaching a plateau 24 h after IFNγ treatment, a time 
point where the Tnf expression had already markedly declined thereby indicating 
different pathways of transcriptional regulation. Induction of immunoproteasomes during 
M1 polarization was confirmed at the protein level for LMP2 and -7 with a marked 
increase after 24 h, further increasing up to day 3. Importantly, expressional changes of 
immunoproteasomes were translated into enhanced formation of active 
immunoproteasomes after 24 h as assessed by a specific set of activity-based probes. 
Previous studies have suggested that immunoproteasome formation can be induced by 
LPS stimulation in RAW 264.7 ascites tumor macrophages, with this interaction being 
critical for NO production but not for the TNF-α expression(160). Although, there is no 
study to describe the transcriptional mechanism for LPS induced immunoproteasome 
expression, we assumed that LPS induced immunoproteasome expression is dependent 
on NF-kB which is the most crucial transcriptional factor downstream of LPS In addition, 
we found the NF-kB binding site in the gene promotor area of LMP2 and LMP7 using a 
public promotor searching software (data not sown). Another indirect mechanism 
involves IFNβ, which has been shown to induce immunoproteasome expression and is 
known to be induced by LPS in macrophages (183). Therefore, it is not surprising to see 
induction of immunoproteasomes by both LPS and IFNγ.  
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Upon M2 polarization, mRNA expression of the immunoproteasome subunits LMP2 and 
-7 was not altered in IL-4-stimulated AMs while MECL-1 expression was slightly 
induced, Both LMP2 and -7 protein expression, however, were significantly elevated by 
IL-4 after 24 h and remained increased for 3 days. Even more important, 
immunoproteasome activity was clearly stimulated during M2 polarization after 48 h of 
IL-4 treatment. Similar to M1 polarization, expression and activity of standard 
proteasomes were also increased. The functional relevance of this regulation, however, 
remains to be determined. Furthermore, we observed that constitutive proteasomes 
were also induced in both M1 and M2 conditions. This is a novel finding and may 
indicate an important role for regulation of constitutive proteasome activity in 
macrophage biology that is worth investigating further. 
So far only little information is available on the role of the immunoproteasome in 
macrophage biology. For the more prominent class of professional antigen-presenting 
cells, i.e. dendritic cells (DC), it has been shown that IFNγ-stimulated DCs upregulate 
the immunoproteasome, whereas IL-4 matured DCs co-express both standard (β1, β2, 
and β5) and immunoproteasome subunits (184). Similar as suggested for DCs, 
enhanced immunoproteasome expressions in M1 and M2 polarized alveolar 
macrophages might also play a role in increased microbicide activity of IFNγ/Th1, or 
improved antigen-presentation at IL-4/Th2 conditions, respectively. Of note, the 
observed posttranscriptional regulation of LMP2 and LMP7 by IL-4 identifies a novel 
regulatory mechanism for immunoproteasome regulation beyond its well-established 
transcriptional activation by IFNγ and TNF-α (185). The kinetics of immunoproteasome 
activation upon M1 or M2 polarization of AM suggest, that up-regulation of proteasome 
3. Chapter 1 - Discussion 
- 74 - 
 
and immunoproteasome activity is a consequence of the altered activation state of 
macrophages, as also suggested for DC differentiation. 
3.4.3. Immunoproteasome function alters macrophage polarization 
Our data reveal a novel role for the immunoproteasome in the innate immune cell 
function, namely macrophage polarization, and thus adds another immune-modulatory 
function to the enigmatic immunoproteasomes beyond their role in adaptive immune 
responses.  
We showed that the absence of specific immunoproteasome subunits, namely LMP2 or 
LMP7, modulates the ability of AMs to polarize towards the M2 phenotype. Such 
disturbance of AM plasticity most likely has important consequences for homeostasis 
and responses to environmental stimuli of the pulmonary tissue. M1 polarization of AMs 
was less affected by LMP2 or LMP7 depletion, and overall marker genes of classical 
activation (Nos2, Tnf, Il1b and Il12b) were largely regulated independently of the 
genotype upon IFNγ/LPS stimulation. This finding is supported by a consistent M1 
profile of well-known pro-inflammatory transcription factors of classical macrophage 
activation which was not altered by immunoproteasome subunit depletion. We conclude 
that LMP2 and -7 are not required for NF-κB1 (p50/p65) signaling during M1 
polarization. The role of immunoproteasomes for canonical NF-κB1 signaling has been 
controversially discussed but can be ruled out for M1 alveolar macrophage 
differentiation (151, 159, 186, 187).  
Remarkably, M2 polarization of AMs was disturbed by immunoproteasome deficiency. 
Our heat map analysis showed that the expression of 21 and 43 M2 signature genes 
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were respectively enhanced, in LMP2-/- or LMP7-/- cells, compared to wt cells. Among 
these genes, 4 well described M2 marker genes (Arg1, Retnla, Ccl17 and Mcr1) were 
selected for the further qPCR validation for their expression, which confirmed the 
enhancement of M2 marker gene expression and thus M2 polarization in LMP2-/- and 
LMP7-/- AMs. Most notably, the IL-4 dependent Th2 chemokine CCL17 was released in 
high amounts from LMP7 and LMP2 deficient AMs. Our findings that LMP2 and -7 
similarly affect M2 polarization were further corroborated by analysis of early signaling 
kinetics upon IL-4 stimulation. In particular, expression of the M2 specific transcription 
factor Irf4 - a key transcription factor that controls M2 macrophage polarization (80) was 
disproportionately higher in M2 polarized LMP2-/- and LMP7-/- cells and its expression 
exceeded wt levels particularly in the first 48 h after IL-4 induction. Similar results were 
obtained for STAT6 and AKT activation, all hallmarks of IL-4 mediated signaling towards 
M2 polarization (83, 188): Both STAT6 and AKT phosphorylation were enhanced in 
LMP2-/- and LMP7-/- cells, respectively. In addition, we are the first to find that IRF4 
expression was induced in M2 but suppressed in M1 AMs, which fits well the literature. 
Previous studies have proven that IRF4 is the downstream target of STAT6 activation, 
and in addition, there is a protein-protein interaction between IRF4 and STAT6. Hence, 
we believe that the IRF4 service is a positive loop to cooperate with STAT6 to derive M2 
markers gene expression. 
These findings clearly reveal that immunoproteasome-deficient AMs have increased 
responsiveness towards IL-4 mediated signaling. Of note, as neither basal nor M1- or 
M2-dependent expression levels of the interleukin 4 receptor alpha (IL-4 ra) genes were 
affected by the LMP genotype, these differences are most probably not due to an altered 
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mRNA expression of the IL-4 receptor but rather due to the altered protein turnover of 
IL-4 receptor. We were thus tempted to speculate that LMP2 and LMP7 affect specific 
substrate degradation in alveolar macrophages, thereby contributing to altered M2 
activation. The proteasome is the cellular machinery which is responsible for cellular 
protein degradation. They are not only responsible for degradation of damaged and 
misfolded proteins during cellular stress, but also for proteins involved in the signaling 
pathway. Thus, the proteasome plays a crucial role in activation of the signaling 
pathways, such as IB is degraded by the proteasome and leads to the activation of 
the NF-κB pathway (189). Khalid W. Kalim has reported that in the differentiation of 
Th17 cells, immunoproteasome inhibition blocked phosphorylation of STAT3, whereas in 
Tregs SMAD phosphorylation was enhanced. Additionally, LMP7 inhibition led to 
reduced STAT1 phosphorylation and Th1 differentiation (155). Although a number of 
studies have indicated that immunoproteasomes are involved in many immune signaling 
pathways, none of these studies identified specific substrates for immunoproteasome-
dependent protein degradation, thus the underlying molecular mechanisms of the effect 
on the above mentioned pathways are largely unclear. We are the first to report that IL-
4Ra is a possible substrate for LMP7-dependent degradation as the deficiency and 
inhibition of LMP7 caused the accumulation of the IL-4Ra protein contributing to the 
observed enhancement of downstream STAT6 and AKT activation. As IL-4Ra is also 
shared by lL-13 to trigger STAT6 dependent M2 polarization, it is not surprising to 
observe enhanced M2 marker gene expression in LMP7 deficient AMs after IL-13 
stimulation. To make sure the increased IL-4Ra protein in LMP7 and LMP2 deficient 
AMs is not due to the adaption effect of the knock out mice strains, we applied the 
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specific LMP7 inhibitor ONX 0914 to the AMs, and found that STAT6 phosphorylation 
was enhanced in ONX 0914 treated AMs, which further lead to the up-regulation of M2 
markers Arg1 and Mrc1. In addition, in order to exclude any unspecific effects of ONX 
0914 on M2 polarization, an ABP-based pulldown assay was performed to confirm the 
specificity of the given dose of ONX 0914 to AMs, and this experiment were done by our 
collaborators (Ilona Keller and Oliver Vosyka) from lab of Silke Meiners of 
Comprehensive Pneumology Center (CPC) of Helmholtz München. Their experiments 
suggested about 50% inhibition of LMP7 with 200 nM and close to 80% inhibition with 1 
µM ONX0914, while β5 was only partially inhibited by about 30% with high doses of 
ONX 0914 (Shanze Chen, Ilona Keller and Oliver Vosyka; Submitted results to Journal 
of Immunology). Thus our inhibitor experiments confirmed that IL-4Ra is regulated by 
the catalytic activity of the immunoproteasome subunit LMP7. Therefore it is worthwhile 
figuring out more substrates of immunoproteasome by using a profiling technique such 
as protein microarray and mass spectrometry, which could help to better understand the 
role of immunoproteasome in disease conditions. For example, it has been well 
described that the Th2 cytokines IL-4  and IL-13 play a crucial role in initiation and 
development of a chronic allergic inflammatory disease asthma by interacting with 
related receptor complexes (190). We have also demonstrated that LMP7 deficiency 
enhances the IL-4 receptor signaling pathway, therefore, theoretically we should able to 
observe aggravated asthma in LMP7 deficient mice. However, Anton Volkov, et al. have 
reported that LMP7 deficiency leads to a reduced Th2 response in the OVA induced 
acute asthma model (191). In this study, the authors were not able to offer an 
explanation for the observed effect due to the complexity of the disease. It is well 
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possible that this effect may be due to the suppression of Th1 and Th17 differentiation 
after LMP7 deficiency. The underlying mechanism for these responses remains to be 
determined, but is certainly related to alter IL-4 receptor signaling in the LMP7 knockout 
cells. In spite of an opposite effect of LMP7 deficiency in the asthma model, it is possible 
to apply our findings to other chronic inflammatory lung disease models. We have 
recently collected data (unpublished), which showed that immunoproteasome subunits 
LMP2 and LMP7 protein levels are induced in whole lung tissue samples from IPF 
patients and BAL fluid the CCL17 protein level is higher in LMP7 deficient mice 
compared with wt mice in a bleomycin induced lung fibrosis model, which may indicate 
the critical role of immunoproteasome in IPF pathogenesis (Shanze Chen and Ilona 
keller, unpublished results). In addition to IPF, our findings may also be applicable to 
COPD as it has been suggested that IL-4/IL-13 signaling contributes to the pathogenesis 
of COPD. IL-4 and IL-13 are known for their capacity to promote mucus production from 
bronchial epithelial cells (192). A transgenic mouse model has revealed that over-
expression of IL-13 in the mouse lung causes emphysema (193). M2 macrophages play 
a crucial role in resolution of inflammation via phagocytosing apoptotic neutrophils (194). 
IL-4 and IL-4Ra were shown to be essential for the resolution of sterile inflammation 
(195) due to enhanced M2 polarization in LMPs deficient macrophages, thereby we 
might observe an enhanced resolution of inflammation in LMPs deficient mice. 
In conclusion, our study demonstrates that LMP2 and LMP7 ablation enhances M2 
polarization of alveolar macrophages, while not impacting M1 polarization. These results 
indicate a crucial role of immunoproteasome in alveolar macrophages biology and 
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suggest the novel potential therapeutic intervention of innate immunity in the lungs by 
inhibition of individual immunoproteasome subunits. 
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4. Chapter 2 : Polarized alveolar macrophage-epithelial cell communication 
4.1. Introduction 
4.1.1. Pulmonary alveolus 
An alveolus is a form of a hollow cavity located in the lung parenchyma, representing the 
terminal end of the respiratory tree and the site of gas exchange with the blood. (196).  
 
Fig 4.1: Scheme of pulmonary alveolus. Copied from http://medicalterms.info/anatomy/Alveoli/ 
There are three major cell types in the alveolar wall (pneumocytes): type I alveolar 
epithelial cells (AEC I), type II alveolar epithelial cells (AEC II) and alveolar 
macrophages (AM). AEC I are squamous, large and thin cells which occupy 90 to 95% 
of the alveolar surface (197). These cells are so thin that they can facilitate the gas 
exchange between the alveoli and the blood (197). AEC I are able to fight against 
microbes and thus initiate the immune responses (198). Currently it is still not clear how 
AEC I are regenerated in the normal lung, but  evidence indicates that AEC I are 
transdifferentiated from AEC II during the alveolar epithelial wound repair(199). AEC II 
are cuboidal cells that constitute around 15% of total lung cells and cover about 7% of 
the total alveolar surface (200). They are responsible for the secretion of surfactant 
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which reduces the alveolar surface tension to increase the gas exchange. In addition to 
the secretion of surfactant, AEC II can also sense the invasion of pathogens and 
produce antimicrobial products such as complement, lysozyme, and antibacterial 
peptide. In addition they can amplify the inflammatory response by secretion of cytokine 
and chemokines (197). As we have introduced in chapter 1, AM is a type of tissue 
macrophage found in the pulmonary alveolus, which has close contact with its 
neighbours AEC I and AEC II. They are one of the key cell types for initiating 
inflammatory and immune responses in the lung.  
4.1.2. Macrophage-epithelial communication 
Cell-to-cell communication is the sharing of information between cells, which serves as 
the basis for functional coordination between cells in multicellular organisms and plays a 
crucial role in cell growth, cell differentiation and tissue homeostasis (201-204). 
Communication between immune and epithelial cells has been suggested to be crucial 
for the fight against the invasion of pathogens to the epithelium (205). In the alveolus, 
one of the critical functions of AEC is to keep the integrity of the epithelial barrier during 
infection and injury. Therefore, the crosstalk between AEC with its neighbor AM is 
required to initiate an appropriate response to invaders, which involves not only the 
killing of microbes but also regulation of tissue repair and resolution of inflammation 
(206).  
There are two ways of communication: contact and non-contact cell-to-cell 
communication. One of the direct contact communications is the gap junction. Close 
adherence of alveolar macrophages to alveolar epithelial cells facilitates sharing of the 
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information through the gap junctions such as connexins (201). Using real-time alveolar 
imaging in situ, Kristin Westphalen et al. showed that the gap junctions called connexin 
43 (Cx43) mediated intercommunication between AMs and alveolar epithelial cells (207). 
These were immunosuppressive signals to reduce endotoxin-induced lung inflammation, 
which involved Ca2+-dependent activation of AKT (207). In contrast to the direct contact 
communication, the non-contact communication has been well investigated involving the 
secreted mediators such as cytokines and chemokines. One example is that microbial 
infections induce M1 polarization of AM and further lead to high production of pro-
inflammatory cytokines IL-1ß, TNF-a, IL-6 and IL-12 from macrophages. As early 
response cytokines, TNF- and IL-1ß further induce the release of chemokines from 
epithelial cells, such as chemokine (C-X-C motif) ligand 1/5 (CXCL1/5) in order to attract 
neutrophils and chemokine (C-C motif) ligand 2 (CCL2) to attract monocytes (208-210). 
Apart from inducing the production of chemoattractant, AM derived TNF-alpha release 
can induce CSF2 (GM-CSF, Granulocyte-macrophage colony-stimulating factor) 
expression in AEC, which in turn initiates AEC proliferation and contributes to alveolar 
barrier integrity (206). In addition, it has been suggested that communication of AM with 
AEC plays a key role in hypoxia-induced lung inflammation affecting the IL-8 release 
(211). Additionally, it has been proven that the macrophage pro-inflammatory cytokine 
IL-1ß augments in vitro alveolar epithelial repair by inducing TGF- and EGF production 
in epithelial cells (212). Hence defective communication in response to damage 
represents a pathophysiological mechanism, which contributes to the development of 
infectious diseases, chronic inflammatory diseases, and cancer.  
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Fig 4.2: The communication of alveolar macrophage with alveolar epithelial cell during pathogen 
infection in the alveolus. As the first line of defense, AM is the first cell type in the alveolus to react to 
the pathogen invasion, afterwards, AM secrete TNF-a and IL-1β, which stimulate the production of  
chemokines from AEC such as CXCL1/5 and CCL2, following that, these chemokines recruit neutrophils 
and monocytes. Adapted from “Fig. 1 of Lidija Cakarova’s thesis: Macrophage-Epithelial Crosstalk 
during Alveolar Epithelial Repair following Pathogen-induced Pulmonary Inflammation”. 
A group of cytokines and chemokines have been reported to be expressed by activated 
epithelial cell.  
IL-6: Interleukin 6 is an interleukin that acts as an inflammatory cytokine via binding to 
IL-6R and activation of STAT3 (213). IL-6 is released by epithelial and macrophages to 
amplify the immune response during inflammation, thereby playing a role in many 
inflammatory diseases (214). 
GM-CSF: Granulocyte-macrophage colony-stimulating factor, also referred to as colony 
stimulating factor 2 (CSF2). It is a monomeric glycoprotein that functions as a white 
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blood cell growth factor, and is secreted by macrophages, T cells, endothelial cells and 
epithelial cells (215). GM-CSF plays the curial role in macrophage biology. Upon 
stimulation of GM-CSF, newly recruited monocytes at the site of inflammation can 
mature into macrophages (216). Bone marrow derived macrophages (BMDM) 
differentiated with GM-CSF display characteristic M1polarization phenotype (217). 
TGF-β: The transforming growth factor beta is a polypeptide cytokine that acts on 
TGFB1R to activate SMADs (218). It is a secreted multifunctional protein that can 
control cell growth, cell proliferation, cell differentiation and apoptosis (219). In addition, 
TGF-β induces trans-differentiation of epithelial cells into mesenchymal cells, a process 
called EMT (220). It has been suggested that TGF-β plays a role in inflammatory lung 
diseases, including lung fibrosis, asthma, COPD (221-223). 
CX3CL1: Chemokine (C-X3-C motif) ligand 1, also known as fractalkine, is constitutively 
expressed by alveolar epithelial cells (224). There is a soluble form of CX3CL1 which 
can potently attract dendritic cells (DC) and monocytes via its receptor CX3CR1, while 
the cell-bound form is responsible for adhesion of leukocytes to activated epithelial cells 
(225, 226). It has been shown that the CX3CL1/CX3CR1 axis is associated with 
inflammatory lung diseases and involved in the recruitment ofCX3CR1+ macrophages in 
the lungs contributing to the development of COPD (226). 
CCL2: chemokine (C-C motif) ligand 2 (CCL2), also called monocyte chemotactic 
protein 1 (MCP1), is the CC family chemokine which attracts monocytes to the sites of 
inflammation via its receptor CCR2 (227). CCL2 is expressed by a variety of cell types 
such as macrophages, epithelial cells and endothelial cells (228). CCL2 is thought to be 
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involved in the pathogenesis of several inflammatory diseases characterized by 
monocyte infiltration (228). The increased concentration of CCL2 in bronchoalveolar 
lavage (BAL) from COPD patients contributes to the recruitment of monocytes that can 
differentiate into macrophages (229). 
LCN2: Lipocalin-2 also known as neutrophil gelatinase-associated lipocalin (NGAL), was 
initially found to be expressed by neutrophils, and is also reported to be induced in 
numerous epithelial cell types in a TLR dependent manner (230). LCN2 can fight against 
the bacterial infection by sequestering iron-containing siderophores (231). In addition, 
LCN2 was shown to promote neutrophil recruitment and trigger G-CSF and CXCL1 in 
alveolar macrophages (232). LCN2 induced macrophage IL-10 formation, skewing 
STAT3 dependent macrophage polarization (233). 
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4.2. Project aims 
The communications between alveolar macrophages and epithelial cells has been 
suggested to play an important role in maintaining the functional integrity of the lung. As 
we have shown in chapter 1, alveolar macrophages can polarize into M1 and M2 
phenotypes upon respective treatment of LPS/IFNγ or IL-4. Epithelial cells, a crucial part 
of the innate lung immunity, establish the local environment of AMs, can release 
chemokines such as CXCL1/5 and CCL2 under inflammatory conditions, and are 
responsible for the recruitment of monocytes and neutrophils in inflamed lung tissue. 
However, the extent of polarized alveolar macrophage-epithelial cell communication 
remains unclear. Therefore, using a trans-well co-culture and conditioned medium model 
depicted in Figure 4.3, we aimed to identify the cellular immune factors derived from 
alveolar macrophages to interact with alveolar epithelial cells. 
 
 
 
 
 
 
                          Fig 4.3: Scheme of trans-well co-culture and conditioned medium model.  
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4.3. Results 
4.3.1. Profiling of polarization markers for the alveolar macrophage cell line MH-S 
As we have shown in the chapter 1, the alveolar macrophages cell line MH-S can be 
polarized into respective M1 and M2 phenotypes upon treatment with either LPS and 
IFNγ or IL-4. Apart from the markers investigated in chapter 1, we found that the mRNA 
level of Cxcl1, Cxcl2, Cxcl9, Il6 and Lipocalin-2 (Lcn2) were also induced in M1 cells, 
while Pparg, Cd36, Cxcr2, Irf4 and Galectin3 (Lgals3) were induced in M2 cells (Fig 4.4). 
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Fig 4.4: Alveolar macrophages cell line MH-S shows characteristics of M1 and M2 polarization by 
maker genes profiling. (A, B) M1 and M2 marker gene expression analysis of MH-S cells polarized for 
24 h: Nos2, Tnf, Il1b, Il12b, Cxcl1, Cxcl2, Cxcl9, Il6 and Lcn2 relative to Actb (β-actin) expression for 
M1, and Arg1, Ccl17, Retnla, Mrc1, Pparg, Cd36, Cxcr2, Irf4 and Galectin3 relative to Actb expression 
for M2. Results are from three independent experiments. 
4.3.2. Polarized M1 AMs activate the LA4 in a transwell co-culture system. 
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To determine if the polarized M1 or M2 alveolar macrophages can communicate with 
alveolar epithelial cells, we introduced a trans-well system to co-culture MH-S with the 
murine alveolar epithelial cell line LA4 separated by a membrane. LA4 were seeded on 
the lower side and MH-S cells on upper side of the trans-well. After 24 h co-culture with 
polarized or non-polarized MHS cell, LA4 cell was prepared for the qPCR profiling. As 
shown in Figure 4.5, we found that the mRNA level of Il6, Lcn2, Csf2, Ccl2 and Cx3cl1 
were induced by LPS/IFNγ not by IL-4 in LA4, while LPS/IFNγ derived expression of 
these cytokines were further enhanced by a co-cultured M1 macrophage. The mRNA 
expression of Tgfb1 was not impacted by either LPS/IFNγ or IL-4 treatment, however, its 
expression was induced in M1 co-cultured LA4 cell.  
4. Chapter 2 - Results 
- 89 - 
 
Il6
Con LPS/IFN IL-4
0.00000
0.00005
0.00010
0.00015
LA4
Co-LA4
*
re
l.
 m
R
N
A
 t
o
 A
c
tb
Csf2
Con LPS/IFN IL-4
0.00000
0.00002
0.00004
0.00006
0.00008
LA4
Co-LA4
***
re
l.
 m
R
N
A
 t
o
 A
c
tb
Lcn2
Con LPS/IFN IL-4
0.00
0.02
0.04
0.06
0.08
0.10
LA4
Co-LA4*
re
l.
 m
R
N
A
 t
o
 A
c
tb
Ccl2
Con LPS/IFN IL-4
0.00
0.05
0.10
0.15
LA4
Co-LA4*
re
l.
 m
R
N
A
 t
o
 A
c
tb
Tgfb1
Con LPS/IFN IL-4
0.000
0.001
0.002
0.003
0.004
LA4
Co-LA4
*
re
l.
 m
R
N
A
 t
o
 A
c
tb
Cx3cl1
Con LPS/IFN IL-4
0
1e-005
2e-005
3e-005
4e-005
LA4
Co-LA4*
re
l.
 m
R
N
A
 t
o
 A
c
tb
 
Figure 4.5: Polarized M1 AMs amplify gene expression from alveolar epithelial cell LA4. 
Gene expression analysis of LA4 co-cultured with polarized or non-polarized MHS cell for 24h: Cx3cl, 
Il6, Lcn2, Csf2, Tgfb1 and Ccl2 relative to Actb (β-actin) expression and Results are mean for three 
replicates. 
4.3.3. Conditioned medium from polarized AMs activate LA4 cells. 
As we wanted to identify secreted mediators and exclude the direct contact effect, we 
further investigated if the conditioned medium from polarized MH-S cell could alter 
mRNA expression of cytokines in LA4 cells. For that, the conditioned medium was 
collected from 24 h M0, M1 and M2 cells, and then added to the LA4 for 24 h. As shown 
in Figure 4.6, we found that the mRNA expression of Il6, Lcn2, Ccl2, and Cx3cl1 was 
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significantly induced by an M1 conditioned medium in LA4; in addition, the mRNA level 
of Cx3cl1 was also induced by an M0 and M2 conditioned medium, however, the 
expression of Csf2 and Tgfb1 were not impacted by any of the conditioned medium. 
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Figure 4.6: Conditioned medium from polarized alveolar macrophage amplifies the expression of 
several genes in alveolar epithelial cells. Gene expression analysis of LA4 cells treated with conditioned 
medium from M0, M1 and M2 cells for 24h: Cx3cl, Il6, Lcn2, Csf2, Tgfb1 and Ccl2 relative to Actb (β-
actin) expression and Results are from three independent experiments. 
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4.3.4. The cytokines TNF-α, IL-1β, IFNγ and IL-17 activate LA4 cells. 
To further determine which cytokines drive gene expression in alveolar epithelial cells in 
a similar manner as observed before in both trans-well co-culture and conditioned 
model, we applied the cytokines TNF-α, IL-1β, IFNγ and IL-17 at concentration of 20 
ng/ml to LA4 cells for 24 h. As shown in Figure 4.5, we found that TNF-α strongly 
induced mRNA level of Ccl2, Cx3cl1 and Csf2 compared with other cytokines, whereas 
IL-1β preferentially induced the expression of Lcn2. 
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Figure 4.7: Macrophage derived pro-inflammatory cytokines TNF-α and IL-1β activate LA4 
cell. Gene expression analysis of LA4 treated with 20ng/ml of TNF-α, IL-1β, IFNγ and IL-17 for 24h: 
Cx3cl, Il6, Lcn2, Csf2, Tgfb1 and Ccl2 relative to Actb (β-actin) expression and Results are mean for two 
replicates. n.d , no detection. 
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4.4. Discussion 
There are many studies using transwell co-cultures and conditions on medium models to 
investigate cytokine mediated communication between epithelial cells and 
macrophages. Using a transwell co-culture model, Jun-Li Ding`s Lab found that M2-
polarized tumor-associated macrophages could promote epithelial–mesenchymal 
transition (EMT) in pancreatic cancer cells via TLR4/IL-10 signaling pathway (234). Olga 
D. Chuquimia, et al. found that the conditioned medium from LPS stimulated AEC 
modulates the activity of alveolar macrophages to control bacterial growth (197). Tiana 
V Curry-McCoy, et al. has suggested that communication between AECs and 
macrophages is involved in the alcohol-induced disruption of the epithelial barrier 
function via TGFβ1 (235). Therefore, epithelial-macrophage communication plays an 
important role in pathogenesis of cancer and inflammatory diseases.  
Here, initially using a trans-well co-culture model, we found that M1 polarized alveolar 
macrophages could enhance the expression of Il6, Tgfb1, Lcn2, Csf2, Ccl2 and Cx3cl1 
in LA4 cells. Furthermore, we proved that conditioned medium from M1 AMs could 
induce the expression of Il6, Lcn2, Ccl2 and Cx3cl1 in LA4 cells but not of Tgfb1 and 
Csf2. However, beyond our expectation, an M0 and M2 conditioned medium can also 
markedly induce the gene expression of Cx3cl1 in LA4 cells. TNF-α and IL-1β as master 
pro-inflammatory cytokines, which are supposed to be mainly derived from 
macrophages have been well described to act on alveolar epithelial cells during the 
acute inflammation. Hence, we used recombinant cytokines to stimulate LA4 cells to test 
whether these factors could be the mediators to induce the gene expression in LA4. We 
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found that the mRNA expression of Ccl2, Cx3cl1 and Csf2 were strongly induced by 
TNF-α, whereas Lcn2 was strongly induced by IL-1β. 
Csf2, a monomeric glycoprotein, is secreted by macrophages, T cells, endothelial cells 
and fibroblasts, and is also expressed by alveolar epithelial cells at lower level (236). 
However, it has been reported that Csf2 expression could be induced in alveolar 
epithelial cells by alveolar macrophage derived TNF-α, and that this stimulation further 
leads to AEC proliferation and repair (206). In addition, expression of Csf2 in AECs is 
important for pulmonary surfactant homeostasis, and deficiency leads to impaired 
alveolar macrophage differentiation and alveolar proteinosis (237, 238). Similarly, we 
found that the Csf2 expression was enhanced in M1 co-cultured LA4 cells, further 
experiments confirmed the induction of Csf2 by TNF-α. However, we observed that IL-
1β can induce the Csf2 expression in LA4 cells to the same extent as well as TNF-α, 
which does not completely align to Lidija Cakarova’s findings. They suggested that it is 
TNF-α from LPS-activated alveolar macrophages that stimulate AECs to express Csf2 
(206). LPS-activated alveolar macrophages have a higher release of IL-1β, but the 
contribution of IL-1β in inducing Csf2 was not investigated. Actually, we are the first to 
show the induction of Csf2 in alveolar epithelial cells by IL-1β.  Robert Newton et al. 
have shown that the IL-1β induced Csf2 expression in A549 cell was repressed by 
glucocorticoids (239).  
IL-6 is usually thought to be a pro-inflammatory cytokine involved in the regulation of the 
immune response and inflammation (240). IL-6 can be produced by numerous cell types 
such as macrophages, endothelial cells and epithelial cells (240). It has been reported 
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long ago that macrophage derived TNF-α and IL-1β can induce the gene expression of 
Il6 (241). Hence, we believe that the increased gene expression of Il6 in LA4 cells as 
shown in Figure 4.5 can be induced by TNF-α or IL-1β. 
Both Ccl2 and Cx3cl1 are chemokines that recruit monocytes to the site of injury and 
inflammation by acting on the respective receptors CCR2 and CX3CR1. It is not 
surprising to observe that M1 cells could induce the Ccl2 up-regulation in LA4 cells. It 
has been demonstrated that silica-induced Ccl2 expressions in alveolar epithelial cells is 
mediated by TNF-α (242). Cx3cl1 is also defined as fractalkine, and was reported to be 
induced by TNF-α and IL-1β in alveolar epithelial cells and fibroblast (243, 244). We also 
observed that M1 cells were able to induce its expression in LA4 cells; however, M0 and 
M2 conditioned media also induced Cx3cl1 in LA4, but that cannot be explained by our 
observation of  no induction of Cx3cl1 in LA4 cell co-culture with the M2 cell.  
TGF-β is a secreted protein which is involved in many cellular processes, including cell 
migration, invasion, EMT, tissue remodeling and immune responses. We observed that 
M1 co-cultured LA4 cells showed an increased TGF-β expression that cannot be 
induced by an M1 conditioned medium. It has been reported that TNF-α promotes TGF-
β expression in lung fibroblasts via AP-1 activation, therefore we believed that the 
increased TGF-β expression in co-culture models may also be induced by TNF-α. In 
terms of the well described role of TGF-β in EMT, as well as M2 cells, it is also possible 
for M1 cells to induce EMT of alveolar epithelial cell through the TGF-β signaling 
pathway. 
4. Chapter 2 - Discussion 
- 95 - 
 
Lipocalin 2 (LCN2), is an antibacterial peptide expressed by macrophage, neutrophils 
and epithelial cells following the microbe induced TLRs activation (245). LCN2 is 
involved in antimicrobial defense by sequestering iron (231). LCN2 is also recognized as 
a biomarker of kidney injury (246). It has been reported that Lcn2 expression can be 
induced by IL-1β in the human alveolar epithelial cell line A549 (247). Similarly, we also 
observed that M1 cells and IL-1β can significantly induce the Lcn2 expression in LA4. 
Interestingly, recent studies indicated an important role of Lcn2 in macrophage 
activation. It has been reported that Lcn2 deficient macrophages showed an enhanced 
M1 polarization via the NF-κB-STAT3 signaling pathway. As we unexpectedly showed 
that IL-1β remarkably induced Lcn2 in LA4 cells, we speculated that the IL-1β activated 
LA4 cell might on their part be able to inhibit M1 polarization by secreted LCN2. 
However to test this hypothesis further co-culture experiments would be required. 
In conclusion, using a trans-well and conditioned medium model as well as several 
individually selected cytokines, we found that M1 polarized alveolar macrophages could 
potentially promote the activation of alveolar epithelial cells through secreted TNF-α and 
IL-1β, which was characterized by the gene expression of Il6, Tgfb1, Lcn2, Csf2, Ccl2 
and Cx3cl1 in LA4 cells. Our findings essentially confirmed the former work from other 
laboratories. 
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5. Materials and methods 
5.1. Materials 
5.1.1. Mice 
All mice were kept and bred at institute of Lung Biology and Disease (iLBD), Helmholtz 
Zentrum München, Neuherberg, according to the national and institutional guidelines. 
Wild type (WT) and LMP2 -/- and LMP7 Knockout mouse are all on a C57BL/6J genetic 
background. The generation of LMP2-/- (Psmb9tm1Stl) or LMP7-/- (Psmb8tm1Hjf) 
mice  have been described in the part of materials & methods in the paper respectively 
from Susumu Tonegawa (248) and  H von Boehmer (249). Mice were age (8-16 weeks) 
and gender matched was sacrificed for BAL cell preparation.  
5.1.2. Commercial available kit 
Kit Name Company 
Absolute qPCR SYBR® Green ROX Mix  Applied Biosystems  
Superscript™ II Reverse Transcriptase kit  Invitrogen 
GoTaq® Polymerase Green Master Mix Promega 
Douset ELISA kit (CCL17) R&D Systems 
Bio-Rad Protein Assay kit Bio-Rad 
RNeasy Mini Kit Qiagen 
High Pure RNA Isolation Kit Roche 
E.Z.N.A.® Viral RNA Kit Omega 
Giemsa and May Grünwald solutions kit Sigma-Aldrich 
Quick-RNA™ MicroPrep kit ZYMO 
RNaseOUT TM Recombinant Ribonuclease Inhibitor Invitrogen 
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dNTP Mix (10mM each) Fermentas 
Activity-based probe assay  Overkleeft Hermen 
S (ABP MV151, ABP LW124 and MVB127) 
ECL-Reagent  GE Health  
 
5.1.3. Equipment 
Equipment Name Company 
NanoDrop® ND-1000 spectrophotometer 
Thermo Scientific, Wilmington, 
USA 
Centrifuge: Eppendorf 5415D 
Eppendorf, Hamburg, 
Germany 
Centrifuge: Sigma 3K18 
Sigma, Osterode am Harz, 
Germany 
ABI PRISM® 7500 detection system 
Applied Biosystems, Foster 
city, CA, USA 
Shandon cytospin3 cytocentrifuge Shandon, PA 
4ml, 15 ml and 50 ml Tubes  
BD Falcon, Heidelberg, 
Germany 
 0.2ml, 0.5ml, 1.5 ml and 2ml Tubes 
Eppendorf, Hamburg, 
Germany 
Vortexer 
Scientific Industries, Karlsruhe, 
Germany 
PCR- thermal cycler : PTC-225 
MJ Research, Hamburg, 
Biozym, Germany 
Pipetman (2μl, 10μl, 20μl, 200μl, 1ml) 
Gilson, Limburg-Offheim, 
Germany 
ABsolute TM QPCR Seal (AB1170) 
Thermo Scientific, Wilmington, 
USA 
96 Wells qPCR plate 
Thermo Scientific, Wilmington, 
USA 
Western Blot system  Bio-Rad , USA 
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5.1.4. Chemicals 
Dulbecco's Modified Eagle Medium (DMEM), Dulbecco's Phosphate buffered saline 
(DPBS), Fetal Bovine Serum (FBS), Fetal Calf Serum (FCS), RPMI Media 1640 and 
antibiotics were purchased from BioChrome (Berlin, Germany) and Invitrogen 
(Karlsruhe, Germany).  
All chemicals were purchased from Invitrogen (Karlsruhe, Germany), Sigma-Aldrich 
(Deisenhofen, Roche (Mannheim, Germany), Germany), Bio-rad (Munich, Germany), 
Fluka (Deisenhofen, Germany), Merck (Darmstadt, Germany), Roth (Karlsruhe, 
Germany) unless otherwise specified. 
5.1.5. Buffers and solutions 
Name Concentration Compounts 
Wash buffer (PBS-T) 1X PBS 
0.05% Tween-20 
PBS buffer (10X) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
TBE buffer (10X) 890 mM Tris Base 
890 mM Boric Acid 
20 mM EDTA (pH 8.0) 
RPMI-1640 medium 1X RPMI-1640 medium 
10% Fetal bovine serum 
1% penicillin/streptomycin 
2 mM glutamine 
50 µM  
ß-mercaptoethanol (for 
macrophage culture) 
Dulbecco's Modified 
Eagle Medium (DMEM) 
1X 
Dulbecco's Modified Eagle 
Medium  
10% Fetal bovine serum 
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1% penicillin/streptomycin 
2 mM glutamine 
50 µM 
ß-mercaptoethanol (for 
macrophage culture) 
RIPA buffer (1X) 20 mM Tris-HCl (pH 7.5) 
150 mM NaCl 
1 mM Na2EDTA 
1 mM EGTA 
1% NP-40 
1% sodium deoxycholate 
2.5 mM sodium pyrophosphate 
1 mM ß-glycerophosphate 
1 mM Na3VO4 
1 μg/ml leupeptin 
loading buffer (2X) 100mM  Tris pH 6,8 
4% SDS 
0,2% Bromphenol blue 
20% Glycero 
Electrophoresis 
(5x)(running) buffer 
15,1 g Tris 
94 g Glycine 
50 ml 10% SDS 
Transfer buffer(1X)              3,02g  Tris  
14,4g  H20 
200ml   Methanol 
10% PAGE (4 gels) 
Resolving 
15,9 ml  H2O  
13,3 ml  30% Acrylamid 
10,0 ml 1.5M Tris pH 8,8 
400 µl 10% SDS 
   400 µl 10% APS 
16 µl TEMED 
10%  PAGE (4 gels) 
Stacking 
13,6 ml H2O  
  3,4 ml 30% Acrylamid 
  2,5 ml 1M Tris pH 6,8 
   200 µl 10% SDS 
200 µl 10% APS 
20 µl TEMED 
Block buffer (ELISA)  1g BSA 
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100ml 1X PBS 
Stop solution (ELISA) 0.18 M H2SO4 
     
5.1.6. Recombinant proteins and antibodies 
 
Name Company 
Anti-p50, p65, Arginase1, IRF4 santa cruz biotechnology 
Anti-LMP2, LMP7, a1-7, IL-4Ra Abcam 
Anti-STAT6, p-STAT6, AKT, p-AKT Cell Signaling 
Anti-iNOS BD Transduction Laboratories 
HRP-conjugated anti-β-actin  Sigma-Aldrich 
Recombinant murine IFN-gamma Immuno tool 
Recombinant murine IL-4, IL-13 Immuno tool 
Lipopolysaccharides (LPS) from E.coli Sigma-Aldrich 
 
5.2. Methods 
5.2.1. Isolation of primary resident alveolar macrophages (AMs) 
Animals were treated humanely and with regard for alleviation of suffering; all animal 
procedures were conducted with approval of the local ethics committee and the 
Bavarian Animal Research Authority of Germany. Mice were anesthetized by 
intraperitoneal injection of a mixture of xylazine (4.1 mg/kg body weight) and ketamine 
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(188.3 mg/kg body weight) and killed by exsanguination (250). Therefore blood was 
drawn from the retroorbital plexus by a capillary. 
Primary alveolar macrophages (AMs) were isolated from the lungs of mice by 
bronchoalveolar lavage (BAL) with 8 washes of 1 ml PBS at room temperature. Cells 
were pelleted for 5 min at 1500 rpm and washed twice in complete RPMI-1640 medium. 
1 x 105 - 5 x 105 cells were seeded in 12- or 24-well plates and were allowed to adhere 
for 1-3 hours. Non-adherent cells were removed by washing two times with PBS 
5.2.2. Alveolar macrophage cell line  
Murine alveolar macrophage cell line (MH-S, derived from BALB/c) was purchased from 
American Type Culture Collection. Cells were grown in complete RPMI-1640 medium 
supplemented with 10 % fetal bovine serum (Biochrom) and 0.05 mM β-
mercaptoethanol and 100 U/ml Penicillin and 100 µg/ml Streptomycin (Gibco) at 37 °C 
and 5 % CO2. When MH-S cells reach confluence, they were washed once in 10 ml 
PBS, and then 5 ml pre-warmed Trypsin-EDTA was added to cover the cell layer. Cells 
were incubated at 37°C for 5 min, and then wait until the complete detachment from the 
flask. Fresh culture medium was added to stop the reaction of Trypsin-EDTA. After 
resuspension in culture medium, MH-S cells were collected in falcon tubes and 
centrifuged (1200 rpm, 5 min, RT). Cells were subsequently diluted at 1:3 ratios into new 
flasks or used in experiments. MH-S cells were splitted every 3 to 4 days. MH-S cells 
were plated on 6-, 12- or 24-well plates with a density of 3 x 105 - 6 x 105 cells/cm2 the 
day before treatment.  
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5.2.3. Polarization of alveolar macrophages into M1 or M2 phenotype 
Primary alveolar macrophages and MH-S cells were polarized towards the M1 
phenotype with LPS (1 μg/ml, Sigma) and/or IFNγ (20 ng/ml, Immunotool) or towards 
the M2 phenotype with IL-4 (20 ng/ml, Immunotool) treatment for up to 72 h. Unpolarized 
cells (M0) served as controls. Cell culture supernatants were collected for measurement 
of CCL17. Adherent AMs were washed twice with PBS and harvested for total RNA 
isolation or protein extraction. 
5.2.4. Trans-well co-culture of alveolar epithelial cell and alveolar macrophage 
For LA4/MH-S co-culture, we used a trans-well co-culture system from (Becton 
Dickinson Lab ware and Corning Incorporated). LA4 were plated seeded on the lower 
side of trans-well at a density of 5.0 x105/well. MH-S cells were seeded on upper side of 
trans-well at a density of 5.0 x105/well. Cells were grown in complete F-12 culture 
medium supplemented with 15 % fetal bovine serum (Biochrom) and 0.05 mM 
nonessential amino acids (NEAA) (Biochrom) and 100 U/ml Penicillin and 100 µg/ml 
Streptomycin (Gibco) at 37 °C and 5 % CO2. After 24h treatment of LPS (1 μg/ml, 
Sigma) and IFNγ(20 ng/ml) or with IL-4(20 ng/ml), RNA from LA4 cells were isolated for 
qPCR profiling. 
5.2.5. Condition medium experiment 
When MH-S cells reach confluence, cells were grown in F-12 culture medium, after the 
stimulation with LPS (1 μg/ml, Sigma) and/or IFNγ (20 ng/ml, Immunotool) toward M1or 
towards the M2 phenotype with IL-4 (20 ng/ml) for 6 h, the culture medium were 
aspirated, and then fresh medium were added again to the cell for another 24h. 
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Followed that, the supernatants from M0, M1and M2 cells were collected as conditioned 
medium, and it was added to the LA4 cell for 24 h. 
5.2.6. Enzyme-Linked Immunosorbent Assay (ELISA) 
Cell culture supernatant of AMs was collected after treatment with LPS/IFNγ and IL-4 for 
M1 and M2 polarization and stored at -80 °C until analysis. CCL17 concentration was 
measured using a specific ELISA (Duoset Detection Kit; R&D Systems) according to the 
manufacturer’s instruction. Concentrations were calculated with a standard curve 
(detection limit 31 pg/ml). 
5.2.7. Transcriptome analysis 
The samples were collected and prepared for RNA isolation by myself. Expressions 
profiling using the Illumina platform were done by Martin Irmler from the core unit from 
the Institute of Experimental Genetics at the Helmholtz Zentrum München. Heatmaps 
were generated with the help of Yuan De Tian from the Institute of Virology at the 
Helmholtz Zentrum München. 
RNA isolation: Total RNA was isolated employing the RNeasy Mini (Qiagen) including 
RNase-Free DNase for digestion of remaining genomic DNA. The Agilent 2100 Bio-
analyzer was used to assess RNA quality and only high quality RNA (RIN>7) was used 
for microarray analysis. 
Expression profiling: Total RNA (about 10 ng) was amplified using the Ovation PicoSL 
WTA System V2 in combination with the Encore Biotin IL Module (Nugen). 1000 ng of 
amplified cDNA was hybridized to Mouse Ref-8 v2.0 Expression Bead Chips (Illumina, 
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San Diego, CA, USA). Staining and scanning were done according to the Illumina 
expression protocol. Data was processed using the GenomeStudioV2011.1 software 
(gene expression module version 1.9.0) in combination with the MouseRef-
8_V2_0_R3_11278551_A.bgx annotation file. The background subtraction option was 
used and an offset to remove remaining negative expression values was introduced. 
CARMAweb was used for quantile normalization (251). 
Statistical transcriptome analysis: Statistical analyses were performed by utilizing the 
statistical programming environment R (R Development Core Team). Genewise testing 
for differential expression was done employing the limma t-test (p<0.05). Heatmaps and 
GO enrichment analysis were done with R/Biocondcutor (www.bioconductor.org). 
5.2.8. Water soluble Tetrazolium salt (WST) cell viability assay 
MHS-cells and primary AMs isolated from Wt and LMPs-/- were seeded to 96 well 
palates at 30,000 per well. After 24h M1 and M2 polarization and serial dose of 
ONX0914 treatment for 6 and 24 h, 10% Roche WST reagent was added to the plate, 
and then wait for 15 min in a CO2-incubator at 37°C, followed that, the results were read 
by spectrophotometer at 490nm.    
5.2.9. RNA extraction and quantitative RT-PCR analysis 
Total RNA was extracted from AMs using Quick-RNA™ MicroPrep kit (ZYMO, Freiburg, 
Germany). 50-1000 ng total RNA was used for cDNA synthesis by Superscript™ II 
Reverse Transcriptase kit with the protocol described previously. To determine the 
expression of target genes relative to the actin housekeeper Actb, the ABsolute™ QPCR 
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SYBR® Green ROX Mix (Thermo Scientific, Wilmington, USA) was used on an ABI 
PRISM® 7000 detection system (Applied Biosystems, Foster city, CA, USA). Primer 
sequences are given in Supplementary Table I. Reaction mixture contained 1 μl cDNA 
(10 ng), 1 μl (5 μM) of each primer, 12.5 μl ROX mix and ddH2O up to a total volume of 
25 μl. Following initial enzyme activation (one cycle at 50°C for 2min and 95 °C for 15 
min), 40 cycles amplification (95 °C for 15 s, 60 °C for 1 min) were carried out, and then 
run a dissociation curve to detect nonspecific amplification. Relative expression of target 
genes and housekeeping gene Actb was calculated according to the 2-ΔCt method (49). 
We chose to show absolute values of a representative single experiment. Results of 
three independent replicates are provided in Table. 
Table 2: Primer sequences and amplicon characteristics of genes of interest (GOI)  
Target 
gene 
Acc. No. Forward primer (5’- 3’) Reverse primer (5’- 3’) 
Actb NM_007393 TCCATCATGAAGTGTGACGT GAGCAATGATCTTGATCTTCAT 
Arg1 NM_007482 GGAACCCAGAGAGAGCATGA TTTTTCCAGCAGACCAGCTT 
Ccl17 NM_011332 TTGTGTTCGCCTGTAGTGCATA CAGGAAGTTGGTGAGCTGGTAA 
Il6 NM_031168 GCC AGA GTC CTT CAG AGA G AGA CTC TCT CCC TTC TGA GC 
Il1b NM_008361 CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 
Il12b NM_008352 GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAAGG 
Irf4 NM_013674 AAAGGCAAGTTCCGAGAAGGG CTCGACCAATTCCTCAAAGTCA 
Irf5 NM_012057 GCCACCTCAGCCGTACAAG CTCCCAGAACGTAATCATCAGG 
Mrc1 NM_008625 CATGAGGCTTCTCCTGCTTCT TTGCCGTCTGAACTGAGATGG 
Nfkb1 NM_008689.2 AGGAAGAAAATGGCGGAGTT GCATAAGCTTCTGGCGTTTC 
Nos2 NM_010927 CCTGTGAGACCTTTGATG CCTATATTGCTGTGGCTC 
Rela NM_009045 CTTGGCAACAGCACAGACC GAGAAGTCCATGTCCGCAAT 
Retnla NM_020509 CGAGTAAGCACAGGCAGT CCAGCTAACTATCCCTCCAC 
Tnf NM_013693 CACCACGCTCTTCTGTCT GGCTACAGGCTTGTCACTC 
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Il4ra NM_001008700 TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG 
Psmd11 NM_178616 GAATGGGCCAAATCAGAGAA TGTACTTCCACCAAAAGGGC 
Psme1 NM_011189 AGG CTT CCA CAC GCA GAT CT ACC AGC TGC CGA TAG TCA CC 
Psme2 NM_001029855 CCA GAT CCT CCA CCC AAG GA CCG GGA GGT AGC CAC ACT TA 
Psme3 NM_011192 TAGCCACGATGGACTGGATG CACAAACACCTTGGTTCCTTGAA 
Psma3 NM_011184.4 TGAAGAAGGCTCCAATAAACGTCT AACGAGCATCTGCCAGCAA 
Psmb5 NM_011186.1 TGCTCGCTAACATGGTGTATCAGTA GGCCTCTCTTATCCCAGCCA 
Psmb6 NM_008946.4 AGACGCTGTCACTTACCAACTTGG AAGAGACTGGCGGCTGTGTG 
Psmb7 NM_011187.1 TGCCTTATGTCACCATGGGTTC TTCCTCCTCCATATCTGGCCTAA 
Psmb8 NM_010724 TGCTTATGCTACCCACAGAGACAA TTCACTTTCACCCAACCGTC 
Psmb9 NM_013585 GTACCGTGAGGACTTGTTAGCGC GGCTGTCGAATTAGCATCCCT 
Psmb10 NM_013640 GAAGACCGGTTCCAGCCAA CACTCAGGATCCCTGCTGTGAT 
Csf-2 NM_009969 GCC ATC AAA GAA GCC CTG GCG GGTCTGCAC ACA TGTTAAA 
Lcn2 NM_008491 GAA GAA CCA AGG AGC TGT TCA ATG CAT TGG TCG GTG 
Tgfb NM_001013025 TGA CGT CAC TGG AGT TGT ACG GGT TCA TGT CAT GGA TGG TGC 
Ccl2 NM_011331 CTT CTG GGC CTG CTG TTC A CCA GCC TAC TCA TTG GGA TCA 
Cx3cl1 NM_009142 GCGACAAGATGACCTCAC CCAGGTGTCACATTGTCC 
Cxcl1 NM_203320 CCG  AAG TCA TAG CCA CAC GTG CCA TCA GAG CAG TCT 
Cxcl5 NM_002994 CCC TAC GGT GGA AGT CAT CTT CAC TGG GGT CAG AGT 
Cxcl2 NM_002089 TCCAGAGCTTGAGTGTGACG TCCAGGTCAGTTAGCCTTGC 
Cxcl9 NM_008599 GGAGTTCGAGGAACCCTA GGGATTTGTAGTGGATCG 
Pparg NM_001127330 GTA GAA GCC GTG CAA GAG GAG GAA CTC CCT GGT CAT 
Cxcr2 NM_009909 AGCAAACACCTCTACTACCCTCTA GGGCTGCATCAATTCAAATACCA 
Cd36 NM_001159555 TGGAGATTACTTTTTCAGTGCAGAA TCCAGCCAATGCCTTTGC 
Galectin3 NM_001145953 GAG CTA CAC ATC CCT AGC C CTC AGG AGG ATC TGA GAC TG 
 
5.2.10. Cell lysis and Western blotting 
For protein isolation, AMs were washed twice with ice cold PBS and lysed with RIPA 
buffer (50 mM Tris•HCl, pH 7.5, 150 mM NaCl, 1 % Nonidet P-40, 0.5 % sodium 
deoxycholate, and 0.1 % SDS). Samples were centrifuged to remove cell debris and 
5. Materials and methods 
- 107 - 
 
protein concentrations were determined using standard Bradford assays. 10 μg of 
protein lysates were separated on 10 % SDS-PAGE and blotted onto polyvinylidene 
difluoride (PVDF) membranes (162-0177, Bio-Rad,). The following antibodies were 
used: LMP2 (ab3328, Abcam), LMP7 (ab3329, Abcam), α1-7 (ab2267, Abcam); IL-4 Rα 
(ab157162, Abcam);  AKT (4685, Cell Signaling), p-AKT (4060, pSer473, Cell 
Signaling), STAT6 (9362, Cell Signaling), p-STAT6 (9361, pTyr641, Cell Signaling); 
IRF4 (M17, Santa Cruz); Arginase1 (H-52, Santa Cruz); iNOS (610331, BD 
Transduction Laboratories); HRP-conjugated anti-β-actin (Sigma); HRP-conjugated anti-
rabbit (Abcam) and anti-goat antibodies (Santa Cruz). 
5.2.11. Activity-based probe labeling of proteasomes  
The samples were collected and prepared for protein isolation by myself. Proteasome 
activity analysis using activity-based probe were done by our collaborator (Oliver 
Vosyka) from lab of Silke Meiners of Comprehensive Pneumology Center (CPC) at the 
Helmholtz Zentrum München.  
Activity of the constitutive and immunoproteasome subunits was monitored by using a 
set of activity-based probes (ABP) (252). The pan-reactive proteasome ABP MV151 
(163) was used for quantification of β-subunit activities. β1/LMP2 activities were 
quantified with the ABP LW124 while quantification of β5/LMP7 subunits was performed 
using the MVB127 ABP(164). 
To obtain native lysates, cells were frozen in liquid nitrogen and thawed in a 37 °C water 
bath for five times in ddH2O supplemented with protease inhibitors. After removal of 
cellular debris, these hypoosmotic lysates were diluted to a total protein concentration of 
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0.5 µg/µl with reaction buffer (50 mM HEPES pH 7.4, 100 mM KCl, 10 mM MgCl2). 30 µl 
of sample was incubated with 0.5 µM MV151, 0.25 µM LW124 or 1 µM MVB127 for 1 h 
at 37 °C respectively and subsequently quenched by the addition of 6x Laemmli Buffer 
(50 % v/v glycerol, 300 mM Tris·HCl, pH 6.8, 6 % w/v SDS, 325 mM DTT, 0.1 % w/v 
bromophenol blue) to a final 1x concentration. 
Samples were separated on a 15 % Tris-glycine SDS polyacrylamide gel and 
proteasome activity was visualized using a fluorescent scanner (Typhoon TRIO+; 
Amersham biosciences). Images were taken at 450 PMT (voltage of photo-multiplier 
tube) and 50 µm pixel resolution with fluorescence Cy3/TAMRA for ABPs MV151 and 
MVB127. The Cy2 florescent channel was used for LW124 and analyzed by using 
ImageJ software (http://imagej.nih.gov/ij/). 
5.2.12. Statistical analysis 
All values are showed as the mean ± SEM of at least five animals or 3 individual 
samples in vitro. We used analysis of variance (ANOVA), as calculated by GraphPad 
Prism 5, to establish the statistical significance of differences between the experimental 
groups. Individual inter-group comparisons were analyzed using the two-tailed unpaired 
t test with Welch's correction. Differences were considered significant at *, p < 0.05; **, 
p<0.01 and ***, p<0.001. 
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7. Abbreviations 
°C Degrees Celsius 
µl Microliter 
Ab Antibody 
Actb Actin, beta 
ALI acute lung injury 
AMs Aveloar macrophages 
BAL Bronchoalveolar lavage 
cDNA Complementary DNA 
COPD chronic obstructive pulmonary disease  
Ct Threshold cycle 
DMEM Dulbecco's Modified Eagle Medium  
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EDTA Ethyldiaminetetraacetate 
ELISA Enzyme-linked immunosorbent assay 
g Gram 
HRP horseradish peroxidase 
KO, -/- Knock out 
L Liter 
LPS Lipopolysaccharides 
M1 macrophages classic activated macrophages 
M2 macrophages alternative activated macrophages 
M-CSF Macrophage colony-stimulating factor 
ml Milliliter 
mm Millimeter 
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells 
OD optical density  
PBS Phosphate buffer saline 
PBST phosphate buffered saline with Tween 20 
PCR Polymerase chain reaction 
qPCR quantitative real-time polymerase chain reaction  
RIPA radioimmunoprecipitation assay buffer 
RNA Ribose nucleic acid 
RT-PCR Reverse transcription PCR 
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SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SPF Specific pathogen-free  
STAT signal transducer and activator of transcription 
TLR Toll-like receptor 
WT Wild type 
HDL high-density lipoprotein 
IRF interferon-regulatory factor 
LMP low molecular mass protein 
MECL1 multicatalytic endopeptidase complex-like 1 
ABP activity-based probe 
Tnf Tumor necrosis factors 
iNOS inducible nitric oxide synthase 
DC dendritic cells  
Il1b Interleukin-1 beta 
Il12b interleukin 12 beta 
IPF Idiopathic pulmonary fibrosis  
IL-4Ra interleukin-4 receptor alpha chain 
Arg1 arginase 1 
Retnla Resistin-like molecule alpha 
Ccl17 Chemokine (C-C motif) ligand 17 
Arg1 arginase 1 
Mrc1 mannose receptor 1 
WT Wild type 
Lcn2 Lipocalin-2 
Tgfb Transforming growth factor beta 
Cxcl5 C-X-C motif chemokine 5 
Il6 interleukin 6 
Ccl2 chemokine (C-C motif) ligand 2 
Csf-2 colony stimulating factor 2 
 
8. Appendix 
- 126 - 
 
8. Appendix 
Lebenslauf 
Persönliche Daten: 
Name:                                      Shanze Chen 
Geschlecht:                              Männlich 
Staatsangehörigkeit:                Chinesisch 
Geburtsdatum/-ort:                   03.04.1985, Anhui, China 
E-mail Adresse:                        shanze.chen@helmholtz-muenchen.de 
 
Schulbildung:  
Nov 2008 - heute:                   Doktorand 
Fach:                                        Humanbiologie 
Betreuer:                                  PD Dr. Silke Meiners und Dr. Tobias Stoeger 
Titel der Arbeit:                 Molecular mechanism of alveolar macrophage polarization and cell 
communication with alveolar epithelial cell 
Adresse: Institut für Lungenbiologie, Helmholtz Zentrum München, Ingolstaedter Landstraße                 
1，D-85764 München, Germany 
Sep 2005 - Oct 2008               Master in Pharmakologie 
Fach:                                        Pharmakologie  
Betreuer:                                  Prof. Ning Huang  
Forschungsthema:                   Unspezifische Immunantwort, antibakterielle Peptide 
Universität:                               Sichuan Universität 
Sep 2001 - Jul 2005                Universitätsstudent   
Fach:                                        Menschen Sport Wissenschaft, Sport Medizin 
Abschluss:                                Bachelor  
Universität:                               Chengdu Sport Universität 
 
Vorträge: 
Alveolar macrophage-epithelial cell interactions in the pathogenesis of carbon nanotube 
induced chronic lung inflammation  
(the 6th International Conference on Nanotoxicology), in Beijing China) 
8. Appendix 
- 127 - 
 
Poster: 
1. Poster 1: Alveolar macrophage-epithelial cell interactions modulate epithelial cell 
activity in a transwell co-culture model. 
(Munich Lung Conference (MLC) 2012, Munich, Germany) 
2. Poster 2: Immunoproteasome subunits LMP2 and LMP7 differentially contribute to 
alveolar macrophage polarization 
(Munich Lung Conference (MLC) 2013, Munich, Germany) 
3. Poster 3: Who is  the main producer of neutrophil-attracting chemokines initiating 
carbon nanoparticle induced acute lung inflammation 
(27th Annual EMDS Meeting, 10 – 12 October 2013, Erlangen, Germany) 
4. Poster 4: Immunoproteasome Subunits LMP2 and LMP7 Differentially Contribute To 
Alveolar Macrophage Polarization  
(ATS 2014 International Conference, San Diego, USA) 
5. Immunoproteasome subunits LMP2 and LMP7 differentially contribute to alveolar 
macrophage polarization 
(ERS International Congress 2014, Munich, Germany) 
Preise: 
Scholarship was provided by China Scholar Council for 48 months (from Nov. 2010 to 
Nov. 2014) 
 
 
 
 
8. Appendix 
- 128 - 
 
Publikationen:  
1. Marianne Geiser, Tobias Stoeger, Marco Casaulta, Shanze Chen, Manuela 
Semmler-Behnke, Ines Bolle, Shinji Takenaka, Wolfgang G Kreyling and Holger 
Schulz. Biokinetics of nanoparticles and susceptibility to particulate exposure in a 
murine model of cystic fibrosis. Part Fibre Toxicol, 2014. 11: p. 19. 
2. Chen Shanze, Renfu Yin, Kathrin Mutze, Oliver Eickelberg, Melanie Königshoff, 
Tobias Stoeger. (2015). Alveolar epithelial cells rather than macrophages initiate 
carbon nanoparticle-induced acute lung inflammation (In preparation for 
Particle and Fibre Toxicology) 
3.  Chen Shanze, Ilona Keller, Oliver Vosyka, Anke-Gabriele Lenz, Oliver Eickelberg, 
Silke Meiners and Tobias Stoeger. (2015). Immunoproteasome dysfunction 
augments alternative polarization of alveolar macrophages. (Submitted to 
Journal of Immunology)
11. Acknowledgements 
- 129 - 
 
9. Acknowledgements 
The completion of my dissertation and subsequent Ph.D. is the biggest event in my life, 
and I very much appreciate the assistance of the many people for their endless and 
countless help and support during the last four and half years. I don’t believe that I would 
have been able to finish my PhD studies without their help. 
Firstly I would like to thank Dr. Tobias Stöger and PD Dr. Silke Meiners for supervising 
me in my PhD project. It has been my privilege to work closely with my supervisors and I 
have enjoyed the opportunity to watch and learn from their knowledge and experience. 
Tobias is a person you just have to like: he is a humorous advisor and one of the most 
knowledgeable people I know. He gave me the freedom to pursue various projects. He 
was my primary resource for getting my science questions answered. Silke is a lively, 
enthusiastic, and energetic person. As my supervisor in the university, she was always 
supportive for my research project. I am also very grateful to her scientific advice and 
knowledge and for many insightful discussions and suggestions. At this point I would like 
to thank my external supervisor Prof. Dr. Barbara Rothen-Rutishauser. She was 
involved in three of my thesis committee meetings and was very helpful in providing 
advice.   
I also want to thank my colleagues in the group of Dynamics of Pulmonary Inflammation 
of the Institute of Lung Biology and Disease (iLBD) for their support and help: Dr. Anke-
Gabriele Lenz, Dr. Furong Tian, Renfu Yin, Nunja Habel, Gabriele Schumann, Birgit 
Frankenberger, Anna Fuchs, Simon Orth, David Kutschke and Raphael Prungnaud and 
the people from the Comprehensive Pneumology Center: Dr. Wolfgang G Kreyling, Dr. 
11. Acknowledgements 
- 130 - 
 
Ali Önder Yildirim, Dr. Melanie Königshoff, Dr. Matthias Wjst, Dr. Otmar Schmid, Dr. 
Koustav Ganguly, Dr. Oana-Veronica Amarie, Bärbel Ritter, Bernd Lentner, Gunter 
Eder, Jie Jia, Qiongman Wang, Katrin Kohse. I want to thank all the people in the 
Institute of Lung Biology and Disease and Comprehensive Pneumology Center, 
particularly our director, Prof. Dr. Oliver Eickelberg. He provided me with an 
international, scientific and friendly atmosphere. 
I would also like to thank my project cooperators Ilona Keller, Dr. Oliver Vosyka and Dr. 
Angela Dann, from the research group, Silke Meiners of the Comprehensive 
Pneumology Center. I would like to thank Martin Irmler and Yuan De Tian for their helps; 
they are also from Helmholtz Zentrum München.  
I am particularly grateful to our secretary Silke Lauer and research school coordinator 
Camille Beuneche, and Dr. Doreen Franke. They helped me to solve problems 
whenever I faced difficulties in my daily life.  
Finally, I would like to acknowledge my family, especially my parents and my younger 
brother for their constant support. They provided unconditional love and care for me. I 
love them so much, and I would not have been able to complete my PhD without them. 
